[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Glioblastoma,Recurrence,Temozolomide,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Battiste<\/b><sup>1<\/sup>, G. Lesser<sup>2<\/sup>, S. Kesari<sup>3<\/sup>, V. Monga<sup>4<\/sup>, T. Walbert<sup>5<\/sup>, K. Sinicrope<sup>6<\/sup>, B. Nabors<sup>7<\/sup>, J. Schroeder<sup>8<\/sup>, E. Wong<sup>9<\/sup>, B. D. Anderson<sup>10<\/sup>, H. Kim<sup>11<\/sup>, S. Kang<sup>12<\/sup>; <br\/><sup>1<\/sup>Oklahoma University, Oklahoma City, OK, <sup>2<\/sup>Wake Forest University, Winston-Salem, NC, <sup>3<\/sup>St. John's Cancer Institute, Santa Monica, CA, <sup>4<\/sup>University California San Francisco, San Francisco, CA, <sup>5<\/sup>Henry Ford Cancer Institute, Detroit, MI, <sup>6<\/sup>Norton Healthcare, Louisville, KY, <sup>7<\/sup>University of Alabama, Burmingham, AL, <sup>8<\/sup>University of Toledo, Toledo, OH, <sup>9<\/sup>Rhode Island Hospital, Providence, RI, <sup>10<\/sup>Theradex Oncology, Princeton, NJ, <sup>11<\/sup>CHA University School of Medicine, Pocheon, Korea, Republic of, <sup>12<\/sup>Oblato Inc., Princeton, NJ","CSlideId":"","ControlKey":"c6c1a4af-04a1-4fd0-8018-a66d55e004da","ControlNumber":"9731","DisclosureBlock":"&nbsp;<b>J. Battiste, <\/b> None.&nbsp;<br><b>G. Lesser, <\/b> <br><b>Oblato<\/b> Grant\/Contract. <br><b>Denovo Biopharma<\/b> Grant\/Contract. <br><b>Novocure<\/b> Grant\/Contract. <br><b>Sumitomo Pharma America<\/b> Grant\/Contract. <br><b>IN8bio<\/b> Other, DSMB Member. <br><b>ONO PHarma<\/b> Other, DSMB Member. <br><b>Servier Pharmaceuticals<\/b> DSMB Member. <br><b>Fortrea<\/b> Other, DSMB Member. <br><b>S. Kesari, <\/b> <br><b>xCures<\/b> Stock. <br><b>Jubilant Biosys; Pyramid Biosciences<\/b> Other, Honoraria. <br><b>Biocept; iCAD; xCures; Nascent; Curtana Pharmaceuticals<\/b> Independent Contractor. <br><b>AADi; Aivita Biomedical; Bavarian Nordic<\/b> Grant\/Contract. <br><b>Bayer; Biocept; Blue Earth Diagnostics<\/b> Grant\/Contract. <br><b>Caris MPI; CNS Pharmaceuticals; EpicentRx; Incyte<\/b> Grant\/Contract. <br><b>Lilly; Oblato; Orbus Therapeutics; Stemedica Cell Technologies<\/b> Grant\/Contract. <br><b>V. Monga, <\/b> <br><b>Astex Pharmaceutical<\/b> Other, Advisory Board. <br><b>Forma Therapeutics<\/b> Other, Advisory Board. <br><b>Amgen<\/b> Grant\/Contract. <br><b>Rising Tide Cancer Research<\/b> Grant\/Contract. <br><b>Glaxo Smith Klein<\/b> Grant\/Contract. <br><b>Dicephera<\/b> Grant\/Contract. <br><b>T. Walbert, <\/b> <br><b>AnHeart<\/b> Other, Advisory Board. <br><b>Servier<\/b> Other, Advisory Board. <br><b>Alexion<\/b> Other, Advisory Board. <br><b>Novocure<\/b> Other, DSMB.<br><b>K. Sinicrope, <\/b> None.&nbsp;<br><b>B. Nabors, <\/b> <br><b>Servier<\/b> Other, Advisory Board. <br><b>Calidi Biotherapeutics<\/b> Other, Advisory Board. <br><b>AnHeart<\/b> Other, Advisory Board. <br><b>CNS Pharma<\/b> Other, DSMB Chairman.<br><b>J. Schroeder, <\/b> None.&nbsp;<br><b>E. Wong, <\/b> <br><b>Novocure<\/b> Grant\/Contract. <br><b>Orbus<\/b> Grant\/Contract. <br><b>Turning Point Therapeutics<\/b> Other, DSMB.<br><b>B. D. Anderson, <\/b> None.&nbsp;<br><b>H. Kim, <\/b> <br><b>Oblato Inc.<\/b> Employment. <br><b>S. Kang, <\/b> <br><b>Oblato Inc.<\/b> Employment.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11536","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT201","PresenterBiography":null,"PresenterDisplayName":"James Battiste, MD, PhD","PresenterKey":"23310124-b799-4551-8bef-ab88aa01212d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT201. Phase 2 clinical trial of OKN-007 in recurrent malignant glioma","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 2 clinical trial of OKN-007 in recurrent malignant glioma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Brain metastasis,ctDNA,Biomarkers,Liquid biopsies,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>N. Kotecki<\/b><sup>1<\/sup>, D. Martins-Branco<sup>1<\/sup>, G. Nader-Marta<sup>1<\/sup>, A. Gombos<sup>1<\/sup>, P. Barthelemy<sup>2<\/sup>, A. Gonçalves<sup>3<\/sup>, E. Borcoman<sup>4<\/sup>, F. Clatot<sup>5<\/sup>, S. Holbrechts<sup>6<\/sup>, E. Stephane de Maio D’Esposito<sup>7<\/sup>, C. Cheymol<sup>8<\/sup>, V. Vanhaudenarde<sup>9<\/sup>, F. Duhoux<sup>10<\/sup>, C. Duhem<sup>11<\/sup>, P. Clement<sup>12<\/sup>, L. Decoster<sup>13<\/sup>, H. Denys<sup>14<\/sup>, F. Lefranc<sup>15<\/sup>, J.-L. Canon<sup>16<\/sup>, J. Gligorov<sup>17<\/sup>, L. Arecco<sup>1<\/sup>, N. Kindt<sup>1<\/sup>, A. Awada<sup>1<\/sup>; <br\/><sup>1<\/sup>Institut Jules Bordet, Brussels, Belgium, <sup>2<\/sup>ICANS Institut Cancérologie Strasbourg Europe, Strasbourg, France, <sup>3<\/sup>Institut Paoli Calmettes, Marseille, France, <sup>4<\/sup>Institut Curie, Paris, France, <sup>5<\/sup>Centre Henri Bequerel, Rouen, France, <sup>6<\/sup>Helora Hôpital de Mons site Kennedy, Mons, Belgium, <sup>7<\/sup>IUCT Oncopole - Institut Claudius Regaud, Toulouse, France, <sup>8<\/sup>Centre Oscar Lambret, Lille, France, <sup>9<\/sup>CHU UCL Namur Sainte-Elisabeth, Namur, Belgium, <sup>10<\/sup>Cliniques Universitaires Saint-Luc, Brussels, Belgium, <sup>11<\/sup>Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg, <sup>12<\/sup>UZ Leuven Gasthuisberg, Leuven, Belgium, <sup>13<\/sup>UZ Brussel, Brussels, Belgium, <sup>14<\/sup>UZ Gent, Gent, Belgium, <sup>15<\/sup>ULB Erasme, HUB, Brussels, Belgium, <sup>16<\/sup>Grand Hôpital de Charleroi, Charleroi, Belgium, <sup>17<\/sup>Institut Universitaire de Cancérologie, AP-HP – Sorbonne Université, Paris, France","CSlideId":"","ControlKey":"cbfbf80d-8ce7-4bd7-81b5-fa87a7cfac19","ControlNumber":"10351","DisclosureBlock":"<b>&nbsp;N. Kotecki, <\/b> <br><b>Byondis<\/b> Travel. <br><b>BMS<\/b> Grant\/Contract. <br><b>Daiichi Sankyo<\/b> Other, -Payment or honoraria for lectures, presentations. <br><b>Astra Zeneca<\/b> Other, -Payment or honoraria for lectures, presentations. <br><b>D. Martins-Branco, <\/b> <br><b>Astra Zeneca<\/b> Other, Payment or honoraria for lectures, presentations. <br><b>Daiichi Sankyo<\/b> Other, Payment or honoraria for lectures, presentations. <br><b>Lilly<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>G. Nader-Marta, <\/b> <br><b>Astra Zeneca<\/b> Travel. <br><b>A. Gombos, <\/b> <br><b>Astra Zeneca<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Daiichi Sankyo<\/b> Travel, Other, Payment or honoraria for lectures, presentations. <br><b>MSD<\/b> Other, Payment or honoraria for lectures, presentations. <br><b>Roche<\/b> Other, Payment or honoraria for lectures, presentations. <br><b>Seagen<\/b> Other, Consulting, Advisory boards. <br><b>Gilead<\/b> Travel. <br><b>Lilly<\/b> Other, Consulting, Advisory boards. <br><b>P. Barthelemy, <\/b> <br><b>BMS<\/b> Travel, Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>MSD<\/b> Travel, Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Astellas Pharma<\/b> Other, Payment or honoraria for lectures, presentations\u000d\u000a. <br><b>Janssen Cilag<\/b> Travel, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Pfizer<\/b> Travel, Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Merck KGaA<\/b> Travel, Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Novartis<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Seagen<\/b> Other, Payment or honoraria for lectures, presentations. <br><b>Ipsen<\/b> Grant\/Contract, Travel, Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Gilead<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Bayer<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Astra Zeneca<\/b> Other, Consulting, Advisory boards. <br><b>Amgen<\/b> Other, Consulting, Advisory boards. <br><b>Eisai<\/b> Other, Consulting, Advisory boards. <br><b>A. Gonçalves, <\/b> <br><b>Astra Zeneca<\/b> Other, - Consulting, Advisory boards. <br><b>Gilead<\/b> Other, - Consulting, Advisory boards. <br><b>MSD<\/b> Other, - Consulting, Advisory boards. <br><b>Novartis<\/b> Other, - Consulting, Advisory boards. <br><b>Mylan<\/b> Travel.<br><b>E. Borcoman, <\/b> None.&nbsp;<br><b>F. Clatot, <\/b> <br><b>Astra Zeneca<\/b> Other, Consulting, Advisory boards. <br><b>Novartis<\/b> Travel, Other, Consulting, Advisory boards. <br><b>MSD<\/b> Other, Consulting, Advisory boards. <br><b>Gilead<\/b> Other, Consulting, Advisory boards. <br><b>Daiichi Sankyo<\/b> Other, Consulting, Advisory boards. <br><b>Merck Sereno<\/b> Other, Consulting, Advisory boards. <br><b>Pfizer<\/b> Travel. <br><b>Nutricia<\/b> Travel. <br><b>S. Holbrechts, <\/b> <br><b>Roche<\/b> Travel. <br><b>Takeda<\/b> Travel. <br><b>BMS<\/b> Other, Consulting, Advisory boards.<br><b>E. Stephane de Maio D’Esposito, <\/b> None..<br><b>C. Cheymol, <\/b> None..<br><b>V. Vanhaudenarde, <\/b> None.&nbsp;<br><b>F. Duhoux, <\/b> <br><b>Amgen<\/b> Travel, Other, Consulting. <br><b>Astra zeneca<\/b> Travel, Other, Consulting. <br><b>Seagen<\/b> Travel, Other, Consulting. <br><b>Gilead<\/b> Travel, Other, Consulting. <br><b>Daiichi Sankyo<\/b> Travel, Other, Consulting. <br><b>Eli Lilly<\/b> Travel, Other, Consulting. <br><b>MSD<\/b> Other, Consulting. <br><b>Novartis<\/b> Travel, Other, Consulting. <br><b>Pierre Fabre<\/b> Travel, Other, Consulting. <br><b>Roche<\/b> Travel, Other, Consulting.<br><b>C. Duhem, <\/b> None.&nbsp;<br><b>P. Clement, <\/b> <br><b>BMS<\/b> Other, Consulting, Advisory boards. <br><b>Abbvie<\/b> Other, Consulting, Advisory boards. <br><b>Vifor Pharma<\/b> Other, Consulting, Advisory boards. <br><b>Merck Serono<\/b> Other, Consulting, Advisory boards. <br><b>Merck Sharp & Dohme<\/b> Other, Consulting, Advisory boards. <br><b>Daiichi Sankyo<\/b> Other, Consulting, Advisory boards. <br><b>LEO pharma<\/b> Other, Consulting, Advisory boards. <br><b>Astra Zeneca<\/b> Grant\/Contract, Other, Consulting, Advisory boards. <br><b>Takeda<\/b> Other, Consulting, Advisory boards. <br><b>MSD<\/b> Other, Consulting, Advisory boards. <br><b>Rakuten<\/b> Other, Consulting, Advisory boards. <br><b>Bayer<\/b> Other, Consulting, Advisory boards. <br><b>Orbus<\/b> Other, Consulting, Advisory boards. <br><b>L. Decoster, <\/b> <br><b>Roche<\/b> - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, advisory boards. <br><b>Astra zeneca<\/b> Travel, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, advisory boards. <br><b>MSD<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, advisory boards. <br><b>BMS<\/b> Other, Consulting, advisory boards. <br><b>Servier<\/b> Other, Consulting, advisory boards. <br><b>H. Denys, <\/b> <br><b>Pfizer<\/b> Travel, Other, Consulting, Advisory boards. <br><b>Roche<\/b> Travel, Other, Consulting, Advisory boards. <br><b>Pharmamar<\/b> Travel, Other, Consulting, Advisory boards. <br><b>Teva<\/b> Travel. <br><b>Astra Zeneca<\/b> Travel, Other, Consulting, Advisory boards. <br><b>Gilead<\/b> Grant\/Contract, Travel, Consulting, Advisory boards. <br><b>MSD<\/b> Travel, Other, Consulting, Advisory boards. <br><b>GSK<\/b> Travel, Other, Consulting, Advisory boards. <br><b>Seagen<\/b> Other, Consulting, Advisory boards. <br><b>Lilly<\/b> Other, Consulting, Advisory boards. <br><b>Novartis<\/b> Other, Consulting, Advisory boards. <br><b>Amgen<\/b> Other, Consulting, Advisory boards.<br><b>F. Lefranc, <\/b> None..<br><b>J. Canon, <\/b> None.&nbsp;<br><b>J. Gligorov, <\/b> <br><b>Eisai<\/b> Grant\/Contract, Other, - Speakers fee\u000d\u000a- Advisory boards. <br><b>Exact Science<\/b> Grant\/Contract, Other, - Speakers fee\u000d\u000a- Advisory boards. <br><b>Seattle Genetics<\/b> Other, - Speakers fee\u000d\u000a- Advisory boards. <br><b>Roche Genentech<\/b> Grant\/Contract, Other, - Speakers fee\u000d\u000a- Advisory boards. <br><b>Daiichi Sankyo<\/b> Other, - Speakers fee\u000d\u000a- Advisory boards. <br><b>Eva Pharm<\/b> Other, - Speakers fee\u000d\u000a- Advisory boards. <br><b>Lilly<\/b> Other, - Speakers fee\u000d\u000a- Advisory boards. <br><b>Merck<\/b> Other, - Speakers fee\u000d\u000a- Advisory boards. <br><b>Novartis<\/b> Other, - Speakers fee\u000d\u000a- Advisory boards. <br><b>Onxeo<\/b> Other, - Advisory boards. <br><b>Pfizer<\/b> Other, - Speakers fee\u000d\u000a- Advisory boards.<br><b>L. Arecco, <\/b> None..<br><b>N. Kindt, <\/b> None.&nbsp;<br><b>A. Awada, <\/b> <br><b>Astra Zeneca<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Eisai<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Daiichi Sankyo<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Amgen<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Bayer<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Genomic Health<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Hengrui<\/b> Other, - Consulting, Advisory boards. <br><b>Innate Pharma<\/b> Other, - Consulting, Advisory boards. <br><b>Ipsen<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>LEO pharma<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Lilly<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Merck<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>MSD<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Novartis<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Pfizer<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Seattle genetics<\/b> Other, - Payment or honoraria for lectures, presentations\u000d\u000a- Consulting, Advisory boards. <br><b>Menarini<\/b> Other, Consulting, Advisory boards. <br><b>BMS<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11537","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT202","PresenterBiography":null,"PresenterDisplayName":"Nuria Kotecki, MD","PresenterKey":"2c36dbfb-500a-4168-a671-4d5bed0034d6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT202. CSFctDNA as a surrogate for tumor tissue DNA in BC pts with CNS metastases: First results from the Brainstorm program (Oncodistinct 006)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"CSFctDNA as a surrogate for tumor tissue DNA in BC pts with CNS metastases: First results from the Brainstorm program (Oncodistinct 006)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Biomarkers,Triple-negative breast cancer (TNBC),Combination therapy,Multiomics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Z. I. Mitri<sup>1<\/sup>, <b>A. L. Creason<\/b><sup>2<\/sup>, J. M. Stommel<sup>2<\/sup>, D. Bottomly<sup>2<\/sup>, J. Lim<sup>2<\/sup>, SMMART Clinical Trials Program, C. L. Corless<sup>2<\/sup>, S. McWeeney<sup>2<\/sup>, G. B. Mills<sup>2<\/sup>; <br\/><sup>1<\/sup>British Columbia Cancer Agency, Vancouver, BC, Canada, <sup>2<\/sup>Knight Cancer Institute, Oregon Health & Science University, Portland, OR","CSlideId":"","ControlKey":"a0b38fbc-4776-4c4b-b4d4-e130f5e8921c","ControlNumber":"10449","DisclosureBlock":"<b>&nbsp;Z. I. Mitri, <\/b> <br><b>AstraZeneca; Daiichi Sankyo\/Astra Zeneca; Gilead Sciences<\/b> Other, Consulting or Advisory Role. <br><b>AstraZeneca; Daiichi Sankyo; GlaxoSmithKline; Lilly; Novartis; Olema Oncology; Radius Health; Seagen<\/b> Other, Research Funding.<br><b>A. L. Creason, <\/b> None..<br><b>J. M. Stommel, <\/b> None..<br><b>D. Bottomly, <\/b> None..<br><b>J. Lim, <\/b> None.&nbsp;<br><b>C. L. Corless, <\/b> <br><b>Omics Data Automation<\/b> Employment, Stock. <br><b>Cepheid<\/b> Travel, Other, Consulting or Advisory Role.<br><b>S. McWeeney, <\/b> None.&nbsp;<br><b>G. B. Mills, <\/b> <br><b>Bluedot; Catena; ImmunoMET; Nuvectis Pharma; SignalChem; Tarveda Therapeutics; Turbine<\/b> Stock, Stock and Other Ownership Interests. <br><b>Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDot; Chrysalis biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog B<\/b> Other, Honoraria. <br><b>Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDot; Chrysalis biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog B<\/b> Other, Consulting or Advisory Role. <br><b>Adelson Medical Research Foundation; AstraZeneca; Breast Cancer Research Foundation; Genentech; GlaxoSmithKline; ImmunoMET; Komipharm; Lilly; NanoString Technologies; Ovarian Cancer Research Foundati<\/b> Other, Research Funding. <br><b>Nanostring Technologies; Myriad Genetics<\/b> Patent, Other Intellectual Property, DSP technology patent with Nanostring; HRD assay to Myriad Genetics. <br><b>AstraZeneca; Chrysalis Biomedical Advisors; ImmunoMET; Michigan Primary Care Consortium; Pfizer; Symphogen<\/b> Travel.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11538","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT203","PresenterBiography":null,"PresenterDisplayName":"Allison Creason, PhD","PresenterKey":"2384c0c4-a3a4-4c75-add6-9831ff7a6310","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT203. Multi-omic analysis of serial biopsies to inform biomarkers of sensitivity to olaparib and durvalumab in patients with metastatic <i>BRCA<\/i>-wildtype triple negative breast cancer (mTNBC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Multi-omic analysis of serial biopsies to inform biomarkers of sensitivity to olaparib and durvalumab in patients with metastatic <i>BRCA<\/i>-wildtype triple negative breast cancer (mTNBC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Metastatic tumors,CNS,pembrolizumab,retifanlimab,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Kamaraju<\/b><sup>1<\/sup>, B. Bayer<sup>2<\/sup>, M. Chang<sup>2<\/sup>, W. Williams<sup>2<\/sup>, C. Wiseman<sup>2<\/sup>, G. Del Priore<sup>2<\/sup>; <br\/><sup>1<\/sup>The Medical College of Wisconsin, Milwaukee, WI, <sup>2<\/sup>BriaCell Therapeutics Corp., Philadelphia, PA","CSlideId":"","ControlKey":"bb02e972-eff0-4d19-9bf4-a0c506b6f2c8","ControlNumber":"10477","DisclosureBlock":"&nbsp;<b>S. Kamaraju, <\/b> None.&nbsp;<br><b>B. Bayer, <\/b> <br><b>BriaCell Therapeutics Corp.<\/b> Employment. <br><b>M. Chang, <\/b> <br><b>BriaCell Therapeutics Corp.<\/b> Employment. <br><b>W. Williams, <\/b> <br><b>BriaCell Therapeutics Corp.<\/b> Employment, Stock. <br><b>C. Wiseman, <\/b> <br><b>BriaCell Therapeutics Corp.<\/b> Independent Contractor. <br><b>Wiseman Research Initiatives LLC<\/b> Other, Managing Member of the LLC. <br><b>Aleph Null Ltd<\/b> Other, Managing Member of Organization. <br><b>Wiseman Cancer Research Foundation, a 501c3 Public Charity<\/b> Other, Charity President. <br><b>G. Del Priore, <\/b> <br><b>BriaCell Therapeutics Corp.<\/b> Employment, Stock.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11539","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT204","PresenterBiography":null,"PresenterDisplayName":"Sailaja Kamaraju, MD","PresenterKey":"554305ac-cca6-477c-8eec-f17023a01748","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT204. Efficacy of Bria-IMT regimen in inducing CNS metastasis regression<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Efficacy of Bria-IMT regimen in inducing CNS metastasis regression<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Breast cancer,Estrogen receptor,Protein kinase C,Tamoxifen,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. P. Goetz<\/b><sup>1<\/sup>, V. J. Suman<sup>1<\/sup>, H. Fraser<sup>2<\/sup>, L. Mina<sup>3<\/sup>, P. Advani<sup>4<\/sup>, R. Leon-Ferre<sup>1<\/sup>, K. Giridhar<sup>1<\/sup>, F. Batalini<sup>5<\/sup>, K. N. Hunt<sup>1<\/sup>, S. Jayaraman<sup>1<\/sup>, J. Jakub<sup>4<\/sup>, P. Cronin<sup>3<\/sup>, M. Piltin<sup>1<\/sup>, A. Degnim<sup>1<\/sup>, J. N. Ingle<sup>1<\/sup>, J. C. Boughey<sup>1<\/sup>, S. Buhrow<sup>1<\/sup>, J. Reid<sup>1<\/sup>, M. Schellenberg<sup>1<\/sup>, J. Hawse<sup>1<\/sup>, S. Quay<sup>2<\/sup>; <br\/><sup>1<\/sup>Mayo Clinic College of Medicine and Science, Rochester, MN, <sup>2<\/sup>Atossa Therapeutics, Seattle, WA, <sup>3<\/sup>Mayo Clinic College of Medicine and Science, Phoenix, AZ, <sup>4<\/sup>Mayo Clinic College of Medicine and Science, Jacksonville, FL, <sup>5<\/sup>Mayo Clinic College Of Medicine, Phoenix, AZ","CSlideId":"","ControlKey":"3e47a522-5e10-4fc6-8562-f3188f7061e5","ControlNumber":"9847","DisclosureBlock":"<b>&nbsp;M. P. Goetz, <\/b> <br><b>Atossa<\/b> Grant\/Contract. <br><b>Sermonix<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Loxo at Lilly<\/b> Grant\/Contract, Travel, Other, consulting with Money to Mayo. <br><b>ARC Therapeutics<\/b> Other, consulting with Money to Mayo. <br><b>Astra Zeneca<\/b> Other, consulting with Money to Mayo. <br><b>Biotheranostics<\/b> Other, consulting with Money to Mayo. <br><b>Biotheryx<\/b> Other, consulting with Money to Mayo. <br><b>BluePrint Medicines<\/b> Other, consulting with Money to Mayo. <br><b>Engage Health Media<\/b> Other, consulting with Money to Mayo. <br><b>Laekna<\/b> Other, consulting with Money to Mayo. <br><b>Novartis<\/b> Other, consulting with Money to Mayo. <br><b>RNA Diagnostics<\/b> Other, consulting with Money to Mayo. <br><b>Seattle Genetics<\/b> Other, DSMB. <br><b>TerSera Therapeutics\/Ampity Health<\/b> Grant\/Contract, Other, consulting with Money to Mayo.<br><b>V. J. Suman, <\/b> None.&nbsp;<br><b>H. Fraser, <\/b> <br><b>Atossa theapeutics<\/b> Employment.<br><b>L. Mina, <\/b> None..<br><b>P. Advani, <\/b> None..<br><b>R. Leon-Ferre, <\/b> None..<br><b>K. Giridhar, <\/b> None..<br><b>F. Batalini, <\/b> None..<br><b>K. N. Hunt, <\/b> None..<br><b>S. Jayaraman, <\/b> None..<br><b>J. Jakub, <\/b> None..<br><b>P. Cronin, <\/b> None..<br><b>M. Piltin, <\/b> None..<br><b>A. Degnim, <\/b> None..<br><b>J. N. Ingle, <\/b> None.&nbsp;<br><b>J. C. Boughey, <\/b> <br><b>Sermonix<\/b> Grant\/Contract.<br><b>S. Buhrow, <\/b> None..<br><b>J. Reid, <\/b> None..<br><b>M. Schellenberg, <\/b> None.&nbsp;<br><b>J. Hawse, <\/b> <br><b>Atossa Therapeutics<\/b> Grant\/Contract. <br><b>S. Quay, <\/b> <br><b>Atossa Therapeutics<\/b> Employment, Stock, Other Business Ownership, Patent.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11540","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT205","PresenterBiography":null,"PresenterDisplayName":"Matthew Goetz, MD","PresenterKey":"0328b6b7-f205-44ca-9ff2-8afc97374d1e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT205. Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Immuno-oncology,trastuzumab,sacituzumab,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Nangia<\/b><sup>1<\/sup>, C. Calfa<sup>2<\/sup>, B. Bayer<sup>3<\/sup>, M. Chang<sup>3<\/sup>, W. Williams<sup>3<\/sup>, G. Del Priore<sup>3<\/sup>, C. Wiseman<sup>3<\/sup>, S. Chumsri<sup>4<\/sup>; <br\/><sup>1<\/sup>Hoag Hospital, Newport Beach, CA, <sup>2<\/sup>University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, <sup>3<\/sup>BriaCell Therapeutics Corp., Philadelphia, PA, <sup>4<\/sup>Mayo Clinic, Jacksonville, FL","CSlideId":"","ControlKey":"f81e7dda-7278-47ec-9ff9-53a3f955d9c3","ControlNumber":"10411","DisclosureBlock":"&nbsp;<b>C. Nangia, <\/b> None..<br><b>C. Calfa, <\/b> None.&nbsp;<br><b>B. Bayer, <\/b> <br><b>BriaCell Therapeutics Corp<\/b> Employment. <br><b>M. Chang, <\/b> <br><b>BriaCell Therapeutics Corp.<\/b> Employment. <br><b>W. Williams, <\/b> <br><b>BriaCell Therapeutics Corp.<\/b> Employment, Stock. <br><b>G. Del Priore, <\/b> <br><b>BriaCell Therapeutics Corp.<\/b> Employment, Stock. <br><b>C. Wiseman, <\/b> <br><b>BriaCell Therapeutics Corp.<\/b> Independent Contractor. <br><b>Wiseman Research Initiatives LLC<\/b> Other, Managing Member of Organization. <br><b>Aleph Null Ltd<\/b> Other, Managing Member of Organization. <br><b>Wiseman Cancer Research Foundation, a 501c3 Public Charity<\/b> Other, President of Charity. <br><b>S. Chumsri, <\/b> <br><b>Bria Cell<\/b> Grant\/Contract, To conduct the phase II trial.. <br><b>Novartis<\/b> Other, Advisory. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Salix<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Other, Advisory.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11541","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT206","PresenterBiography":null,"PresenterDisplayName":"Chaitali Nangia, MD","PresenterKey":"af88def0-5d17-4b9b-b610-f1174c3d876a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT206. Efficacy and safety of SV-BR-1-GM after progression on ADC in metastatic breast cancer patients","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Efficacy and safety of SV-BR-1-GM after progression on ADC in metastatic breast cancer patients","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Biomarkers,PD-L1,Gene expression profiling,Squamous cell carcinoma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Å. Bratland<\/b><sup>1<\/sup>, J.-J. Grob<sup>2<\/sup>, E. Munoz Couselo<sup>3<\/sup>, L. Mortier<sup>4<\/sup>, R. Gutzmer<sup>5<\/sup>, O. Roshdy<sup>6<\/sup>, R. Mendoza Gonzalez<sup>7<\/sup>, J. Schachter<sup>8<\/sup>, A. M. Arance Fernandez<sup>9<\/sup>, F. Grange<sup>10<\/sup>, N. Meyer<sup>11<\/sup>, A. J. A. Joshi<sup>12<\/sup>, S. Billan<sup>13<\/sup>, J. Shen<sup>14<\/sup>, R. Cristescu<sup>14<\/sup>, M. Nebozhyn<sup>14<\/sup>, A. Loboda<sup>14<\/sup>, J. Sparkowski<sup>14<\/sup>, B. Gumuscu<sup>14<\/sup>, J. Yuan<sup>14<\/sup>, B. Hughes<sup>15<\/sup>; <br\/><sup>1<\/sup>Oslo University Hospital, Oslo, Norway, <sup>2<\/sup>Aix-Marseille University, Assistance Publique Hopitaux de Marseille (APHM), Marseille, France, <sup>3<\/sup>Vall d'Hebron Hospital, Barcelona, Spain, <sup>4<\/sup>Universite Lille, Centre Hospitalier Regional Universitaire de Lille, Lille, France, <sup>5<\/sup>Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany, <sup>6<\/sup>McGill University, Montreal, QC, Canada, <sup>7<\/sup>Centro Estatal de Cancerologia de Chihuahua, El Bajo, Mexico, <sup>8<\/sup>Sheba Medical Center, Tel HaShomer Hospital, Ramat Gan, Israel, <sup>9<\/sup>Hospital Clinic de Barcelona, Barcelona, Spain, <sup>10<\/sup>CHU Reims - Hôpital Robert Debre, Reims, France, <sup>11<\/sup>Clinique Médipôle Garonne, Toulouse, France, <sup>12<\/sup>Townsville Cancer Center, Currajong, Australia, <sup>13<\/sup>Rambam Health Care Campus, Technion-Israel Institute of Technology, Haifa, Israel, <sup>14<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>15<\/sup>Royal Brisbane & Women's Hospital, and University of Queensland, Herston, QLD, Australia","CSlideId":"","ControlKey":"5d3cb052-0588-49f2-a9a3-e4ca57729843","ControlNumber":"10754","DisclosureBlock":"<b>&nbsp;Å. Bratland, <\/b> <br><b>MSD<\/b> Other, Invited Speaker, Principal Investigator, Advisory Role. <br><b>Sanofi<\/b> Other, Invited Speaker, Advisory Board. <br><b>BMS<\/b> Other, Invited Speaker, Principal Investigator. <br><b>Sun Pharma<\/b> Other, Invited Speaker, Advisory Board. <br><b>J. Grob, <\/b> <br><b>Novartis<\/b> Travel, Advisory Board. <br><b>MSD<\/b> Travel, Advisory Board, Speaker. <br><b>BMS<\/b> Travel, Advisory Board, Speaker. <br><b>Philogen<\/b> Other, Advisory Board\u000d\u000aSpeaker. <br><b>Pierre Fabre<\/b> Travel, Advisory Board, Speaker. <br><b>Sanofi<\/b> Travel, Ad Board, Speaker. <br><b>E. Munoz Couselo, <\/b> <br><b>BMS<\/b> Travel, Other, Consulting Fee, Honoria, Advisory Board. <br><b>MERCK SERONO<\/b> Travel, Other, Consulting Fee, Honoria. <br><b>AMGEN<\/b> Other, Consulting Fees. <br><b>PIERRE FABRE<\/b> Other, Consulting Fee, Hononria. <br><b>SANOFI<\/b> Other, Consulting Fees. <br><b>NOVARTIS<\/b> Travel, Other, Honoria. <br><b>ROCHE<\/b> Other, Consulting Fees. <br><b>SUN PHARMA<\/b> Travel. <br><b>L. Mortier, <\/b> <br><b>MSD<\/b> Travel. <br><b>MERCK<\/b> Travel. <br><b>NOVARTIS<\/b> Travel. <br><b>BMS<\/b> Travel. <br><b>Pierre fabre<\/b> Travel. <br><b>R. Gutzmer, <\/b> <br><b>BMS<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor. <br><b>Merck Sharp and Dohme<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor. <br><b>Novartis<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor, Funding. <br><b>Merck-Serono<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor, Funding. <br><b>Amgen<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor, Funding. <br><b>Almirall Hermal<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor, Funding. <br><b>Pierre-Fabre<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor, Support for Meeting Participation. <br><b>Sun Pharma<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor, Funding, Support for Meeting Participation. <br><b>Immunocore<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor. <br><b>4SC<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor. <br><b>Delcath<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor. <br><b>Sanofi\/Regeneron<\/b> Other, Invited Speaker, Writing Engagements, Advisory Board, Principal Investigator, Sponsor, Funding. <br><b>KyowaKirin<\/b> Other, Funding. <br><b>Boehringer Ingelheim<\/b> Other, Support for Meeting Participation.<br><b>O. Roshdy, <\/b> None..<br><b>R. Mendoza Gonzalez, <\/b> None..<br><b>J. Schachter, <\/b> None..<br><b>A. M. Arance Fernandez, <\/b> None.&nbsp;<br><b>F. Grange, <\/b> <br><b>Sanofi-Adventis<\/b> Consulting Fees. <br><b>BMS<\/b> Honoria, Support for attending meetings and\/or travel. <br><b>N. Meyer, <\/b> <br><b>BMS<\/b> Grant\/Contract, Travel, Other, Advisory Boards, Consultant or Speaker, Investigator. <br><b>MSD<\/b> Grant\/Contract, Travel, Other, Advisory Boards, Consultant or Speaker, Investigator. <br><b>Pierre Fabre<\/b> Travel, Other, Advisory Boards, Consultant or Speaker, Investigator. <br><b>Novartis<\/b> Other, Advisory Boards, Consultant or Speaker, Investigator. <br><b>Sanofi<\/b> Other, Advisory Boards, Consultant or Speaker, Investigator. <br><b>Roche<\/b> Other, Investigator. <br><b>A. J. A. Joshi, <\/b> <br><b>BMS<\/b> Other, Invited Speaker, Principal Investigator, Advisory Role. <br><b>MSD<\/b> Other, Invited Speaker, Principal Investigator, Advisory Role. <br><b>Roche<\/b> Other, Principal Investigator, Advisory Role. <br><b>Novartis<\/b> Other, Advisory Board, Sponsor\/Funding. <br><b>Ipsen<\/b> Other, Invited Speaker.<br><b>S. Billan, <\/b> None.&nbsp;<br><b>J. Shen, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment, Other, Stocks\/Shares. <br><b>R. Cristescu, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment, Other, Full-time employment, Stock\/Share holder. <br><b>M. Nebozhyn, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>A. Loboda, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>J. Sparkowski, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>B. Gumuscu, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>J. Yuan, <\/b> <br><b>Merck<\/b> Employment, Full\/Part-Time Employment, Stock\/Shares. <br><b>B. Hughes, <\/b> <br><b>Merck Sharpe and Dohme<\/b> Other, Provision of study materials. <br><b>Amgen<\/b> Grant\/Contract. <br><b>Eisai<\/b> Other, Speakers Bureau.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11542","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT207","PresenterBiography":null,"PresenterDisplayName":"Marie Ross","PresenterKey":"7bfa46ee-60cd-4dcc-b207-c5f4d99d86ae","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT207. Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent\/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent\/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Checkpoint Inhibitors,Tumor microenvironment,Single cell,Monocyte,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>H. S. Fuchs<\/b><sup>1<\/sup>, S. A. James<sup>1<\/sup>, T. M. Carroll<sup>1<\/sup>, P. F. Xie<sup>1<\/sup>, J. A. Chadwick<sup>1<\/sup>, D. Parkes<sup>1<\/sup>, S. R. Lord<sup>2<\/sup>, L. Griffiths<sup>3<\/sup>, T. Underwood<sup>4<\/sup>, I. Karydis<sup>4<\/sup>, R. T. Petty<sup>5<\/sup>, B. Schuster-Böckler<sup>1<\/sup>, R. P. Owen<sup>1<\/sup>, M. R. Middleton<sup>6<\/sup>, X. Lu<sup>1<\/sup>; <br\/><sup>1<\/sup>Ludwig Institute for Cancer Research, Oxford, Oxford, United Kingdom, <sup>2<\/sup>Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, Oxford, United Kingdom, <sup>3<\/sup>Oncology Clincial Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, United Kingdom, <sup>4<\/sup>University of Southampton, Southampton, United Kingdom, <sup>5<\/sup>University of Dundee, Dundee, United Kingdom, <sup>6<\/sup>Department of Oncology, University of Oxford, Oxford, United Kingdom","CSlideId":"","ControlKey":"392cb3fc-58f0-41ef-b4ae-2a8e2f5e6f99","ControlNumber":"9838","DisclosureBlock":"&nbsp;<b>H. S. Fuchs, <\/b> None..<br><b>S. A. James, <\/b> None.&nbsp;<br><b>T. M. Carroll, <\/b> <br><b>Cleancard (diagnostics)<\/b> Employment, Stock.<br><b>P. F. Xie, <\/b> None..<br><b>J. A. Chadwick, <\/b> None..<br><b>D. Parkes, <\/b> None.&nbsp;<br><b>S. R. Lord, <\/b> <br><b>Mitox Therapeutics<\/b> Stock. <br><b>Esai; Pfizer: Prosigna; Roche; Sanofi; Shionogi; GLG Consulting; Rejuversen; Novartis; Synthon; CRUK; Boehringer Ingelheim; Piqur Therapeutics; AstraZeneca; Carrick Therapeutics; Merck KGaA<\/b> Other, Consulting fees or honoraria. <br><b>Pathios Therapeutics<\/b> Research Funding. <br><b>Pfizer<\/b> Other, Previous employment.<br><b>L. Griffiths, <\/b> None..<br><b>T. Underwood, <\/b> None.&nbsp;<br><b>I. Karydis, <\/b> <br><b>BMS; Delcath Inc; Immunocore; Pierre Fabre; Genentech; Merck Serono; Takeda Pharmaceuticals Int.<\/b> Other, Honoraria. <br><b>R. T. Petty, <\/b> <br><b>Bristol-Myers Squib; SERVIER<\/b> Other, Consulting\/Advisory Role (incl. Honoraria). <br><b>AstraZeneca; Basilea (Inst); Five Prime Therapeutics (Inst); Merck Serono (Inst); MSD Oncology (Inst); Roche (Inst)<\/b> Other, Research funding.<br><b>B. Schuster-Böckler, <\/b> None..<br><b>R. P. Owen, <\/b> None.&nbsp;<br><b>M. R. Middleton, <\/b> <br><b>Bayer; Boehringer Ingelheim<\/b> Other, Consulting\/Advisory Role. <br><b>AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Immunocore (Inst); Infinitopes (Inst); Mural Oncology (Inst); Replimune (Inst)<\/b> Other, Research funding. <br><b>X. Lu, <\/b> <br><b>SimCell<\/b> Other, Consulting.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11543","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT208","PresenterBiography":null,"PresenterDisplayName":"Hannah Fuchs, MSPH","PresenterKey":"c270ffc4-e579-4aa6-8fed-e168023c8f49","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT208. High tumor monocyte content predicts long-term survival for patients with operable oesophageal cancer treated with neoadjuvant immunochemotherapy in the LUD2015-005 trial","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"High tumor monocyte content predicts long-term survival for patients with operable oesophageal cancer treated with neoadjuvant immunochemotherapy in the LUD2015-005 trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Cancer immunotherapy,Paclitaxel,Chemotherapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Z. Lu, Y. Cao, L. Dai, <b>F. Dong<\/b>, L. Shen; <br\/>Peking University Cancer Hospital, Beijing, China","CSlideId":"","ControlKey":"c8dc1b3f-bca8-4d3c-8cc4-c981cb2feb0c","ControlNumber":"9714","DisclosureBlock":"&nbsp;<b>Z. Lu, <\/b> None..<br><b>Y. Cao, <\/b> None..<br><b>L. Dai, <\/b> None..<br><b>F. Dong, <\/b> None..<br><b>L. Shen, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11544","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT209","PresenterBiography":null,"PresenterDisplayName":"Fengxiao Dong, MD","PresenterKey":"d75ece65-60ac-4b4d-b4e4-9dd4a90a6cb2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT209. Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): A single-center, randomized, phase II trial","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): A single-center, randomized, phase II trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Hepatocellular carcinoma,Sorafenib,Pembrolizumab,Immunomodulation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Renuka Iyer<\/b><sup>1<\/sup>, Sahithi Sonti<sup>1<\/sup>, Devalingam Mahalingam<sup>2<\/sup>, Sarbajit Mukherjee<sup>1<\/sup>, Sayan Chakraborty<sup>1<\/sup>, Kristopher Attwood<sup>1<\/sup>, Anthony George<sup>1<\/sup>, Orla Maguire<sup>1<\/sup>, Hans Minderman<sup>1<\/sup>, Christos Fountzilas<sup>1<\/sup><br><br\/><sup>1<\/sup>Roswell Park Comprehensive Cancer Center, Buffalo, NY,<sup>2<\/sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL","CSlideId":"","ControlKey":"57aa3cfd-6f21-4f5c-8a06-d822fe7fabce","ControlNumber":"9922","DisclosureBlock":"<b>&nbsp;R. Iyer, <\/b> <br><b>Lexicon<\/b> Other, Consulting\/Advisory. <br><b>Novartis<\/b> Other, Consulting\/Advisory. <br><b>Eisai<\/b> Other, Consulting\/Advisory. <br><b>Merck<\/b> Other, Consulting\/Advisory. <br><b>Bayer<\/b> Other, Consulting\/Advisory. <br><b>Advanced Accelerator Applications<\/b> Other, Consulting\/Advisory. <br><b>Exelixis<\/b> Other, Consulting\/Advisory. <br><b>Sun pharma<\/b> Other, Consulting\/Advisory. <br><b>QED Therapeutics<\/b> Other, Consulting\/Advisory. <br><b>Ipsen<\/b> Other, Consulting\/Advisory. <br><b>Sandoz<\/b> Other, Consulting\/Advisory. <br><b>Tersera<\/b> Other, Consulting\/Advisory. <br><b>AstraZeneca<\/b> Other, Consulting\/Advisory. <br><b>Incyte<\/b> Other, Consulting\/Advisory. <br><b>Genetech<\/b> Other. <br><b>Replimmune<\/b> Other. <br><b>Astrazeneca<\/b> Other. <br><b>Genentech\/Roche<\/b> Grant\/Contract. <br><b>Ipsen; Lilly<\/b> Grant\/Contract.<br><b>S. Sonti, <\/b> None.&nbsp;<br><b>D. Mahalingam, <\/b> <br><b>OncoOne<\/b> Other, Consulting\/Advisory. <br><b>Amgen<\/b> Other, Consulting\/Advisory. <br><b>Qurient<\/b> Other, Consulting\/Advisory. <br><b>Bristol-Myers Squibb<\/b> Other, Speakers' Bureau. <br><b>Amgen<\/b> Other, Speakers' Bureau. <br><b>Exelixis<\/b> Other, Speakers' Bureau. <br><b>Eisai<\/b> Other, Speakers' Bureau. <br><b>Genentech<\/b> Other, Speakers' Bureau. <br><b>Merck KGaA<\/b> Grant\/Contract. <br><b>Oncolytics<\/b> Grant\/Contract. <br><b>S. Mukherjee, <\/b> <br><b>Esophageal Cancer Action Network (ECAN)<\/b> Other. <br><b>Ipsen<\/b> Grant\/Contract.<br><b>S. Chakraborty, <\/b> None..<br><b>K. Attwood, <\/b> None..<br><b>A. George, <\/b> None..<br><b>O. Maguire, <\/b> None..<br><b>H. Minderman, <\/b> None.&nbsp;<br><b>C. Fountzilas, <\/b> <br><b>CG Pharmaceuticals<\/b> Travel. <br><b>Merck; Lilly; Astellas Pharma<\/b> Grant\/Contract. <br><b>Rafael Pharmaceuticals; Pfizer<\/b> Grant\/Contract. <br><b>Seagen; Corcept Therapeutics<\/b> Grant\/Contract. <br><b>Ipsen<\/b> Grant\/Contract. <br><b>Erytech Pharma<\/b> Grant\/Contract. <br><b>Taiho Oncology<\/b> Grant\/Contract. <br><b>Kadmon<\/b> Grant\/Contract. <br><b>Dragonfly Therapeutics<\/b> Grant\/Contract. <br><b>Aravive<\/b> Grant\/Contract. <br><b>Bristol-Myers Squibb\/Ono Pharmaceuticals<\/b> Grant\/Contract. <br><b>TransThera Biosciences<\/b> Grant\/Contract. <br><b>CrystalGenomics<\/b> Grant\/Contract. <br><b>Bellicum Pharmaceuticals<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Biomea Fusion<\/b> Grant\/Contract. <br><b>Amgen<\/b> Grant\/Contract. <br><b>Valar Labs<\/b> Grant\/Contract. <br><b>Sanofi<\/b> Grant\/Contract.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11545","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT210","PresenterBiography":null,"PresenterDisplayName":"Sahithi Sonti, MBBS","PresenterKey":"93940c31-24c5-48f3-9e69-4919bd917beb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT210. Phase Ib\/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase Ib\/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Durvalumab,Hepatitis B virus,Immune checkpoint blockade,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y.-Y. Shao<\/b><sup>1<\/sup>, C.-T. Chen<sup>2<\/sup>, T.-C. Wu<sup>2<\/sup>, T.-H. Liu<sup>1<\/sup>, C.-H. Chuang<sup>3<\/sup>, A.-L. Cheng<sup>1<\/sup>, C.-H. Hsu<sup>1<\/sup>; <br\/><sup>1<\/sup>National Taiwan University Hospital, Taipei, Taiwan, <sup>2<\/sup>National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan, <sup>3<\/sup>National Taiwan University Cancer Center, Taipei, Taiwan","CSlideId":"","ControlKey":"890db0e2-c406-4c4a-9666-0e43bba6ca6c","ControlNumber":"9511","DisclosureBlock":"<b>&nbsp;Y. Shao, <\/b> <br><b>AstraZeneca<\/b> Travel. <br><b>Roche<\/b> Travel.<br><b>C. Chen, <\/b> None..<br><b>T. Wu, <\/b> None..<br><b>T. Liu, <\/b> None..<br><b>C. Chuang, <\/b> None..<br><b>A. Cheng, <\/b> None..<br><b>C. Hsu, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11546","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT211","PresenterBiography":null,"PresenterDisplayName":"Yu-Yun Shao, MD;PhD","PresenterKey":"025a38bb-b615-49a5-ad0c-980f9172f35c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT211. Safety of prompt initiation of durvalumab or STRIDE (single tremelimumab regular interval durvalumab) regimen as hepatocellular carcinoma (HCC) treatment for patients with chronic active hepatitis B","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Safety of prompt initiation of durvalumab or STRIDE (single tremelimumab regular interval durvalumab) regimen as hepatocellular carcinoma (HCC) treatment for patients with chronic active hepatitis B","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,atezolizumab,etrumadenant,MORPHEUS,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>K.-P. Kim<\/b><sup>1<\/sup>, M. Ponz Sarvise<sup>2<\/sup>, T. Macarulla<sup>3<\/sup>, A. Alistar<sup>4<\/sup>, E. O'Reilly<sup>5<\/sup>, M. Boakye<sup>6<\/sup>, H. Prizant<sup>7<\/sup>, T. Xu<sup>8<\/sup>, F. Young<sup>9<\/sup>, J. Lau<sup>7<\/sup>, D.-Y. Oh<sup>10<\/sup>, J. Lacy<sup>11<\/sup>; <br\/><sup>1<\/sup>Asan Medical Center (AMC), Seoul, Korea, Republic of, <sup>2<\/sup>Universidad de Navarra, Pamplona, Spain, <sup>3<\/sup>Vall d'Hebron University Hospital, Barcelona, Spain, <sup>4<\/sup>Atlantic Medical Group, Morristown, NJ, <sup>5<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>6<\/sup>Arcus Biosciences, Hayward, CA, <sup>7<\/sup>Genentech Inc., South San Francisco, CA, <sup>8<\/sup>F. Hoffmann-La Roche Ltd., Mississauga, ON, Canada, <sup>9<\/sup>F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom, <sup>10<\/sup>Seoul National University College of Medicine, Seoul, Korea, Republic of, <sup>11<\/sup>Yale School of Medicine, New Haven, CT","CSlideId":"","ControlKey":"bb87151e-565f-4e24-b156-d9c38435ab4c","ControlNumber":"9618","DisclosureBlock":"<b>&nbsp;K. Kim, <\/b> <br><b>F. Hoffmann-La Roche, Ltd.<\/b> Other, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.&nbsp;<br><b>M. Ponz Sarvise, <\/b> <br><b>F. Hoffmann-La Roche, Ltd<\/b> Grant\/Contract, Other, Travel\/meeting support; Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.. <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Travel\/Meeting support. <br><b>T. Macarulla, <\/b> <br><b>MSD, Novocure, QED Therapeutics, Roche Farma, Sanofi-Aventis, Servier, Zymeworks<\/b> Grant\/Contract. <br><b>AbbVie Farmaceútica, Ability Pharmaceuticals, Agios Pharmaceuticals, Amgen, Aslan Pharmaceuticals, AstraZeneca, Basilea Pharmaceutica International, Bayer, BeiGene, BioKeralty Research Institute<\/b> Grant\/Contract. <br><b>BioLineRx, Blueprint Medicines, Boston Biomedical, Bristol Myers Squibb, Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-La Roche, FibroGen, Halozyme, Incyte, Ipsen Bioscience, Ipsen Pharma<\/b> Grant\/Contract. <br><b>Lilly, Loxo Oncology, MedImmune, Merck Sharp & Dohme, Nelum, Novartis, Novocure, OncoMed Pharmaceuticals, QED Therapeutics, VCN Biosciences, Zymeworks<\/b> Grant\/Contract. <br><b>Ability Pharmaceuticals SL, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, , Incyte, Ipsen Bioscience Inc<\/b> Other, Consulting fees. <br><b>Janssen, Lilly<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Servier, AstraZeneca, Sanofi,  Incyte, Lilly and MSD<\/b> Travel. <br><b>Ability Pharmaceuticals SL, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, , Incyte, Ipsen Bioscience Inc<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>F. Hoffmann-La Roche Ltd<\/b> Other, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.&nbsp;<br><b>A. Alistar, <\/b> <br><b>Astra Zeneca, BMS, Seagen<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Rafael Pharmaceutical, Natera<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>Merck Pharmaceutical<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events\u000d\u000a\u000d\u000aParticipation on a Data Safety Monitoring Board or Advisory Board. <br><b>F. Hoffmann-La Roche Ltd<\/b> Other, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.&nbsp;<br><b>E. O'Reilly, <\/b> <br><b>Seagen, Boehringer Ingelheim, BioNTech, Ipsen, Merck, IDEAYA, Silenseed, Novartis, AstraZeneca, Noxxon, BioSapien, Cend Therapeutics, Thetis, Autem, ZielBio, Tempus, Agios, Genentech-Roche, Eisai<\/b> Other, Advisory\/consulting. <br><b>Zymeworks<\/b> Other, Advisory\/consulting. <br><b>Genentech\/Roche, Celgene\/BMS, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute<\/b> Other, Research funding. <br><b>F. Hoffmann-La Roche Ltd<\/b> Other, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.&nbsp;<br><b>M. Boakye, <\/b> <br><b>Arcus Biosciences<\/b> Other, All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.). <br><b>F. Hoffmann-La Roche Ltd<\/b> Other, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.&nbsp;<br><b>H. Prizant, <\/b> <br><b>Genentech Inc.\/F. Hoffmann-La Roch, Ltd.<\/b> Employment, Stock, Other, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.&nbsp;<br><b>T. Xu, <\/b> <br><b>F. Hoffmann-La Roche, Ltd.<\/b> Employment, Stock, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.&nbsp;<br><b>F. Young, <\/b> <br><b>F. Hoffmann-La Roche, Ltd.<\/b> Employment, Stock, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.&nbsp;<br><b>J. Lau, <\/b> <br><b>Genentech, Inc.<\/b> Employment, Stock. <br><b>F. Hoffmann-La Roche Ltd<\/b> Other, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.. <br><b>Arcus Biosciences<\/b> Other. <br><b>D. Oh, <\/b> <br><b>F. Hoffmann-La Roche Ltd<\/b> Other, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.. <br><b>Array, Eli Lilly, Servier, BeiGene, MSD, Handok<\/b> Grant\/Contract. <br><b>Genentech\/Roche, Merck Serono , Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS\/Celgene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA, MSD, LG Chem, Astellas, Abbvie, J-Pharma<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>Mirati Therapeutics, Eutilex<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>AstraZeneca, Novartis, BeiGene<\/b> Grant\/Contract, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>J. Lacy, <\/b> <br><b>Guidepoint, Equinox, KeyQuest, Techspert, First Word Group, Aptitude Health, Deciphera<\/b> Other, Consulting fees. <br><b>ASCO-SEP<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Novartis<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board\u000d\u000a\u000d\u000aConsulting fees. <br><b>Genentech, Ipsen, BMS<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>Rath, Young and Pignatelli, P.C.<\/b> Other, Other financial or non-financial interests. <br><b>F. Hoffmann-La Roche Ltd<\/b> Other, Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11547","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT212","PresenterBiography":null,"PresenterDisplayName":"Kyu-Pyo Kim, MD;PhD","PresenterKey":"28da013e-23d0-45d1-a41c-c83738de7931","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT212. Phase Ib\/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase Ib\/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,First-line,Liver metastases,Anlotinib,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Wu<\/b><sup>1<\/sup>, C. Zhou<sup>1<\/sup>, J. Yan<sup>2<\/sup>, Z. Han<sup>3<\/sup>, C. Wang<sup>2<\/sup>, Z. Qin<sup>4<\/sup>, J. Jiang<sup>1<\/sup>, C. Wang<sup>5<\/sup>, X. Tang<sup>6<\/sup>, L. Zhu<sup>7<\/sup>, J. Chen<sup>8<\/sup>, Y. Mao<sup>9<\/sup>, X. Wei<sup>10<\/sup>, C. Shangguan<sup>1<\/sup>, J. Zhang<sup>1<\/sup>; <br\/><sup>1<\/sup>Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, <sup>2<\/sup>Department of Oncology, Jiading Central Hospital, Shanghai, China, <sup>3<\/sup>Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China, <sup>4<\/sup>Department of Oncology, Zhejiang Provincial People's Hospital, Hangzhou, China, <sup>5<\/sup>Department of Oncology, Yancheng Third People‘s Hospital, Yancheng, China, <sup>6<\/sup>Department of Oncology, Wuxi Branch of Ruijin Hospital, Wuxi, China, <sup>7<\/sup>Department of Oncology, Jiangsu Province Hospital, Nanjing, China, <sup>8<\/sup>Department of Oncology, The Affiliated People’s Hospital of Ningbo University, Ningbo, China, <sup>9<\/sup>Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China, <sup>10<\/sup>Department of Oncology, Nanjing First Hospital, Nanjing, China","CSlideId":"","ControlKey":"c1dd14df-ef08-41cc-9e98-b965f03a7c72","ControlNumber":"9516","DisclosureBlock":"&nbsp;<b>J. Wu, <\/b> None..<br><b>C. Zhou, <\/b> None..<br><b>J. Yan, <\/b> None..<br><b>Z. Han, <\/b> None..<br><b>C. Wang, <\/b> None..<br><b>Z. Qin, <\/b> None..<br><b>J. Jiang, <\/b> None..<br><b>C. Wang, <\/b> None..<br><b>X. Tang, <\/b> None..<br><b>L. Zhu, <\/b> None..<br><b>J. Chen, <\/b> None..<br><b>Y. Mao, <\/b> None..<br><b>X. Wei, <\/b> None..<br><b>C. Shangguan, <\/b> None..<br><b>J. Zhang, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11548","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT213","PresenterBiography":null,"PresenterDisplayName":"Junwei Wu, MD","PresenterKey":"699ac479-02c9-4da3-81d4-375c127a0779","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT213. Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Vitamin D,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Propper<\/b><sup>1<\/sup>, G. Jameson<sup>2<\/sup>, D. Roe<sup>3<\/sup>, B. Wertheim<sup>3<\/sup>, D. Von Hoff<sup>4<\/sup>, E. H. Borazanci<sup>2<\/sup>; <br\/><sup>1<\/sup>Barts & The London NHS Trust, London, United Kingdom, <sup>2<\/sup>HonorHealth Research Institute, Scottsdale, AZ, <sup>3<\/sup>University of Arizona, Tucson, AZ, <sup>4<\/sup>TGen, Phoenix, AZ","CSlideId":"","ControlKey":"f08f6d53-72bb-49d0-a7fd-4c18e05b4fe9","ControlNumber":"10679","DisclosureBlock":"&nbsp;<b>D. Propper, <\/b> None..<br><b>G. Jameson, <\/b> None..<br><b>D. Roe, <\/b> None..<br><b>B. Wertheim, <\/b> None..<br><b>D. Von Hoff, <\/b> None.&nbsp;<br><b>E. H. Borazanci, <\/b> <br><b>BPG<\/b> Other, Consulting. <br><b>Clearnote<\/b> Other, Consulting. <br><b>Elevation Oncology<\/b> Other, Consulting. <br><b>Nanology<\/b> Other, Consulting. <br><b>Qurient<\/b> Other, Consulting. <br><b>Vivacitus<\/b> Other, Consulting.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11549","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT214","PresenterBiography":null,"PresenterDisplayName":"David Propper, MBChB;MD","PresenterKey":"8ab00100-49aa-42cd-b4b7-083f509a0f7b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT214. Paricalcitol addition to chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PINBALL)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Paricalcitol addition to chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PINBALL)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"HER2\/neu,Esophageal cancer,Gastrointestinal cancers: stomach,Vaccines,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Tobias<\/b><sup>1<\/sup>, M. Kundi<sup>1<\/sup>, E. Garner-Spitzer<sup>1<\/sup>, C. Zielinski<sup>1<\/sup>, M. Maglakelidze<sup>2<\/sup>, Z. Andric<sup>3<\/sup>, Z. Petrovic<sup>4<\/sup>, R. Nagarkar<sup>5<\/sup>, T. Chawla<sup>6<\/sup>, L. Chong<sup>7<\/sup>, B. Nixon<sup>7<\/sup>, S. Yavrom<sup>7<\/sup>, N. J. Ede<sup>7<\/sup>, U. Wiedermann<sup>1<\/sup>; <br\/><sup>1<\/sup>Medical University of Vienna, Vienna, Austria, <sup>2<\/sup>ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia, <sup>3<\/sup>Clinical Hospital Center Bezanijska, Belgrade, Serbia, <sup>4<\/sup>Military Medical Academy, Belgrade, Serbia, <sup>5<\/sup>CG Manavata Cancer Centre, Nashik, India, <sup>6<\/sup>Tata Medical Center, Kolkata, India, <sup>7<\/sup>Imugene Limited, Sydney, Australia","CSlideId":"","ControlKey":"66b18ee0-8df5-4d7b-8260-89f4af103634","ControlNumber":"9684","DisclosureBlock":"&nbsp;<b>J. Tobias, <\/b> None..<br><b>M. Kundi, <\/b> None..<br><b>E. Garner-Spitzer, <\/b> None.&nbsp;<br><b>C. Zielinski, <\/b> <br><b>Athenex<\/b> Other, Consultation. <br><b>MSD<\/b> Other, Consultation. <br><b>Imugene Patent, Other, Consultation (until Sept 2018).<\/b> Other, Consultation (until Sept 2018). <br><b>AstraZeneca<\/b> Other, Consultation, Institutional. <br><b>Servier<\/b> Other, Consultation, Institutional. <br><b>Eli Lilly<\/b> Other, Consultation, Institutional. <br><b>BMS<\/b> Other, Institutional. <br><b>MSD<\/b> Other, Institutional. <br><b>Pfizer<\/b> Other, Institutional. <br><b>Merck KgaA<\/b> Other, Institutional. <br><b>Amgen<\/b> Other, Institutional. <br><b>Takeda<\/b> Other, Institutional. <br><b>Daiichi Sankyo<\/b> Other, Institutional. <br><b>Roche<\/b> Other, Institutional. <br><b>Boehringer<\/b> Other, Institutional. <br><b>Celgene<\/b> Other, Institutional. <br><b>Halozyme<\/b> Other, Institutional.<br><b>M. Maglakelidze, <\/b> None..<br><b>Z. Andric, <\/b> None..<br><b>Z. Petrovic, <\/b> None..<br><b>R. Nagarkar, <\/b> None..<br><b>T. Chawla, <\/b> None.&nbsp;<br><b>L. Chong, <\/b> <br><b>Imugene Limited<\/b> Other, Leadership. <br><b>B. Nixon, <\/b> <br><b>Imugene Limited<\/b> Other, Employment. <br><b>Imugene Limited<\/b> Other, Shareholder\/Stockholder. <br><b>S. Yavrom, <\/b> <br><b>Imugene Limited<\/b> Other, Employment. <br><b>N. J. Ede, <\/b> <br><b>Imugene Limited<\/b> Other, Employment. <br><b>U. Wiedermann, <\/b> <br><b>Imugene Limited<\/b> Other, CSO (until Sept 2018). <br><b>GSK<\/b> Other, Funding to the Institute. <br><b>Pfizer<\/b> Other, Funding to the Institute. <br><b>Themis<\/b> Other, Funding to the Institute.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11550","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT215","PresenterBiography":null,"PresenterDisplayName":"Joshua Tobias, Dr PH","PresenterKey":"d832bdeb-8102-4834-a2bd-b4720b680bb2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT215. Frontline vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+ metastatic or advanced gastric\/GEJ adenocarcinoma - Final results from Phase II\/HERIZON study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Frontline vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+ metastatic or advanced gastric\/GEJ adenocarcinoma - Final results from Phase II\/HERIZON study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Gastrointestinal cancers: stomach,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"D.-H. Koo<sup>1<\/sup>, J.-Y. Kim<sup>2<\/sup>, J.-J. Kim<sup>3<\/sup>, S. Y. Oh<sup>4<\/sup>, M.-H. Ryu<sup>5<\/sup>, D. Y. Zang<sup>6<\/sup>, <b>H. K. Kim<\/b><sup>7<\/sup>; <br\/><sup>1<\/sup>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, <sup>2<\/sup>Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of, <sup>3<\/sup>Pusan National University Yangsan Hospita, Yangsan, Korea, Republic of, <sup>4<\/sup>Dong-A University Hospital, Pusan, Korea, Republic of, <sup>5<\/sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>6<\/sup>Hallym University  College of Medicine, Pyeongchon, Korea, Republic of, <sup>7<\/sup>National Cancer Center - Korea, Goyang, Korea, Republic of","CSlideId":"","ControlKey":"9a68484e-859b-4ee8-b20b-9fa9df2bdaf0","ControlNumber":"10816","DisclosureBlock":"&nbsp;<b>D. Koo, <\/b> None..<br><b>J. Kim, <\/b> None..<br><b>J. Kim, <\/b> None..<br><b>S. Y. Oh, <\/b> None..<br><b>M. Ryu, <\/b> None..<br><b>D. Y. Zang, <\/b> None.&nbsp;<br><b>H. K. Kim, <\/b> <br><b>Standigm<\/b> Grant\/Contract.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11551","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT216","PresenterBiography":null,"PresenterDisplayName":"Hark Kim, MD;PhD","PresenterKey":"88d10c27-85cc-40ad-8d9e-49089cd9b13c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT216. Anti-EGFR in combination with paclitaxel as second-line therapy for gastric cancer with EGFR overexpression","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Anti-EGFR in combination with paclitaxel as second-line therapy for gastric cancer with EGFR overexpression","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Colon cancer,Immunotherapy,Immunogenic cell death,Immune checkpoint,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Thibaudin<\/b>, J.-D. Fumet, E. Limagne, L. Hampe, S. Daumoine, V. Derangère, C. Laheurte, O. Adotevi, C. Truntzer, F. Ghiringhelli; <br\/>CENTRE GEORGES FRANCOIS LECLERC, Dijon, France","CSlideId":"","ControlKey":"ef7df5bf-392b-4536-b665-a40de2ca99a2","ControlNumber":"10715","DisclosureBlock":"&nbsp;<b>M. Thibaudin, <\/b> None..<br><b>J. Fumet, <\/b> None..<br><b>E. Limagne, <\/b> None..<br><b>L. Hampe, <\/b> None..<br><b>S. Daumoine, <\/b> None..<br><b>V. Derangère, <\/b> None..<br><b>C. Laheurte, <\/b> None..<br><b>O. Adotevi, <\/b> None..<br><b>C. Truntzer, <\/b> None..<br><b>F. Ghiringhelli, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11552","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT217","PresenterBiography":null,"PresenterDisplayName":"Marion Thibaudin","PresenterKey":"bd756e3d-728c-42cb-ba0c-7f79cb4b6a3d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT217. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Transcriptional regulation,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Propper<\/b><sup>1<\/sup>, E. Borazanci<sup>2<\/sup>, P. J. O'Dwyer<sup>3<\/sup>, D. Von Hoff<sup>4<\/sup>, J. Hartlebury<sup>1<\/sup>, C. E. Antal<sup>5<\/sup>, G. I. Evan<sup>6<\/sup>, H. Han<sup>7<\/sup>, M. Downes<sup>8<\/sup>, R. Evans<sup>8<\/sup>, J. Rabinowitz<sup>9<\/sup>, E. Petricoin<sup>10<\/sup>, A. Saluja<sup>11<\/sup>, M. Velagapudi<sup>12<\/sup>, H. Patel<sup>13<\/sup>; <br\/><sup>1<\/sup>Barts Cancer Institute, London, United Kingdom, <sup>2<\/sup>HonorHealth Research Institute, Scottsdale, AZ, <sup>3<\/sup>University of Pennsylvania, Philadelphia, PA, <sup>4<\/sup>TGen\/HonorHealth, Phoenix, AZ, <sup>5<\/sup>UC San Diego, La Jolla, CA, <sup>6<\/sup>University of Cambridge, Cambridge, United Kingdom, <sup>7<\/sup>TGen, Phoenix, AZ, <sup>8<\/sup>The Salk Institute, La Jolla, CA, <sup>9<\/sup>Princeton University, Princeton, NJ, <sup>10<\/sup>George Mason University, Manassas, VA, <sup>11<\/sup>University of Miami Medical Group, Miami, FL, <sup>12<\/sup>Minneamrita Therapeutics LLC, Tampa, FL, <sup>13<\/sup>UCSD Moores Cancer Center, La Jolla, CA","CSlideId":"","ControlKey":"2bcdef12-3fe1-45dd-ba53-3826b7d84908","ControlNumber":"9916","DisclosureBlock":"<b>&nbsp;D. Propper, <\/b> <br><b>BPGbio<\/b> Other, Advice board honoraria. <br><b>Bristol-Myers Squibb<\/b> Other, Advice board honoraria. <br><b>Servier<\/b> Other, Speakers honoraria. <br><b>E. Borazanci, <\/b> <br><b>BPG<\/b> Other, Advisory board. <br><b>Clearnote<\/b> Other, consulting. <br><b>Conjupro<\/b> Other, consulting. <br><b>ElevationOncology<\/b> Other, consulting. <br><b>Nanology<\/b> Other, consulting. <br><b>Vivacitus<\/b> consulting. <br><b>Qurient<\/b> Other, consulting. <br><b>P. J. O'Dwyer, <\/b> <br><b>Pfizer<\/b> Other, Research Support. <br><b>BMS<\/b> Other, Research Support. <br><b>GSK<\/b> Other, Research Support. <br><b>Merck<\/b> Other, Research Support. <br><b>Syndax<\/b> Other, Research Support. <br><b>BBI<\/b> Other, Research Support. <br><b>Novartis<\/b> Other, Research Support. <br><b>Celgene<\/b> Other, Research Support. <br><b>Incyte<\/b> Other, Research Support. <br><b>Liily\/imclone<\/b> Other, Research Support. <br><b>Array<\/b> Other, Research Support. <br><b>h3biomedicine<\/b> Other, Research Support. <br><b>Taiho<\/b> Other, Research Support. <br><b>Minneamrita<\/b> Other, Research Support. <br><b>pharmacyclics\/abbvie<\/b> Other, Research Support. <br><b>Mirati<\/b> Other, Research Support. <br><b>D. Von Hoff, <\/b> <br><b>Medtronic<\/b> Stock. <br><b>CerRx<\/b> Stock. <br><b>SynDevRx<\/b> Stock. <br><b>UnitedHealthcare<\/b> Stock. <br><b>Anthem Inc<\/b> Stock. <br><b>Stromatis Pharma<\/b> Stock. <br><b>Systems Oncology<\/b> Stock. <br><b>Stingray Therapeutics<\/b> Stock. <br><b>FORMA Therapeutics<\/b> Stock. <br><b>Orpheus Bioscience<\/b> Stock. <br><b>AADi<\/b> Stock. <br><b>Origin Commercial Advisors<\/b> Stock. <br><b>Halia Therapeutics<\/b> Stock. <br><b>(3+2) Pharma<\/b> Stock. <br><b>Lycia Therapeutics<\/b> Stock. <br><b>Imaging Endpoints<\/b> Consulting. <br><b>Senhwa Biosciences<\/b> Consulting. <br><b>Alpha Cancer Technologies<\/b> Consulting. <br><b>CanBas<\/b> Consulting. <br><b>Lixte Biotechnology<\/b> Consulting.<br><b>J. Hartlebury, <\/b> None..<br><b>C. E. Antal, <\/b> None..<br><b>G. I. Evan, <\/b> None..<br><b>H. Han, <\/b> None..<br><b>M. Downes, <\/b> None..<br><b>R. Evans, <\/b> None.&nbsp;<br><b>J. Rabinowitz, <\/b> <br><b>Faeth Therapeutics<\/b> Other, \u0009\u000d\u000aScientific Advisory Board. <br><b>Marea Therapeutics<\/b> Other, \u0009\u000d\u000aScientific Advisory Board. <br><b>Empress Therapeutics<\/b> Other, \u0009\u000d\u000aScientific Advisory Board. <br><b>Rafael Holdings<\/b> Other, \u0009\u000d\u000aScientific Advisory Board. <br><b>Raze Therapeutics<\/b> Other, \u0009\u000d\u000aBoard of Directors. <br><b>Farber Partners<\/b> Other, Co-Founder and Board of Directors. <br><b>Bantam Pharmaceuticals<\/b> Other, Scientific Advisory Board. <br><b>Bantam Pharmaceuticals<\/b> Other, Scientific Advisory Board. <br><b>L. E. A. F.<\/b> Other, Scientific Advisor. <br><b>Colorado Research Partners<\/b> Other, Scientific Advisor. <br><b>Sofro Pharmaceuticals<\/b> Other, Founder and Board of Directors. <br><b>E. Petricoin, <\/b> <br><b>Perthera Inc<\/b> Stock, Other, paid consultation  and stock equity. <br><b>Theralink Technologies Inc:<\/b> Stock, Other, paid consultation  and stock equity. <br><b>Ceres Nanosciences Inc<\/b> Stock Option, Other, paid consultation  and stock equity. <br><b>Deciphera Therapeutics<\/b> Grant\/Contract. <br><b>Springworks Therapuetics<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>A. Saluja, <\/b> <br><b>Minneamrita Therapeutics<\/b> Other, Chief Scientific Officer and co-founder of Minneamrita Therapeutics. <br><b>M. Velagapudi, <\/b> <br><b>Minneamrita Therapeutics<\/b> Stock, Other, Chief Executive Officer and co-founder of Minneamrita Therapeutics.<br><b>H. Patel, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11553","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT218","PresenterBiography":null,"PresenterDisplayName":"David Propper, MBChB;MD","PresenterKey":"8ab00100-49aa-42cd-b4b7-083f509a0f7b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT218. Phase II open label trial of Minnelide&#8482; in patients with chemotherapy refractory metastatic pancreatic cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase II open label trial of Minnelide&#8482; in patients with chemotherapy refractory metastatic pancreatic cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Focal adhesion kinase (FAK),Kinase inhibitors,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>T.-A. Cock<\/b><sup>1<\/sup>, A. Bishop<sup>1<\/sup>, N. Kruger<sup>1<\/sup>, S. McCormack<sup>1<\/sup>, M. Harris<sup>2<\/sup>, S. Ananda<sup>3<\/sup>, L. Lipton<sup>4<\/sup>, A. Nagrial<sup>5<\/sup>, N. Pavlakis<sup>6<\/sup>, W. Joubert<sup>7<\/sup>, L. Donato<sup>8<\/sup>, J. Lickliter<sup>1<\/sup>, C. Burns<sup>1<\/sup>; <br\/><sup>1<\/sup>Amplia Therapeutics, Melbourne, Australia, <sup>2<\/sup>Monash Medical Centre, Melbourne, Australia, <sup>3<\/sup>Epworth Cancer Services Clinical Institute, Melbourne, Australia, <sup>4<\/sup>Sunshine Hospital, Melbourne, Australia, <sup>5<\/sup>Westmead Cancer Care Centre, Sydney, Australia, <sup>6<\/sup>GenesisCare, Sydney, Australia, <sup>7<\/sup>Greenslopes Oncology, Brisbane, Australia, <sup>8<\/sup>IQVIA Biotech, Sydney, Australia","CSlideId":"","ControlKey":"61ef4fbc-ada7-41a5-a8fb-bb9447ef0af3","ControlNumber":"10869","DisclosureBlock":"&nbsp;<b>T. Cock, <\/b> None..<br><b>A. Bishop, <\/b> None..<br><b>N. Kruger, <\/b> None..<br><b>S. McCormack, <\/b> None..<br><b>M. Harris, <\/b> None..<br><b>S. Ananda, <\/b> None..<br><b>L. Lipton, <\/b> None..<br><b>A. Nagrial, <\/b> None..<br><b>N. Pavlakis, <\/b> None..<br><b>W. Joubert, <\/b> None..<br><b>L. Donato, <\/b> None..<br><b>J. Lickliter, <\/b> None..<br><b>C. Burns, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11555","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT220","PresenterBiography":null,"PresenterDisplayName":"Terrie-Anne Cock, D Phil","PresenterKey":"fc460700-c504-41e9-9892-bf2428646f3d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT220. Phase 1b\/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane) standard of care as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1b\/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane) standard of care as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Hypoxia-inducible factor,Renal cell carcinoma,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. Srinivasan<\/b><sup>1<\/sup>, O. Iliopoulos<sup>2<\/sup>, K. E. Beckermann<sup>3<\/sup>, V. Narayan<sup>4<\/sup>, B. L. Maughan<sup>5<\/sup>, S. Oudard<sup>6<\/sup>, T. Else<sup>7<\/sup>, J. K. Maranchie<sup>8<\/sup>, A. B. Iversen<sup>9<\/sup>, J. Cornell<sup>10<\/sup>, R. F. Perini<sup>10<\/sup>, Y. Liu<sup>10<\/sup>, W. M. Linehan<sup>1<\/sup>, E. Jonasch<sup>11<\/sup>; <br\/><sup>1<\/sup>Center for Cancer Research, National Cancer Institute, Bethesda, MD, <sup>2<\/sup>Mass General Cancer Center and Harvard Medical School, Boston, MA, <sup>3<\/sup>Vanderbilt University Medical Center, Nashville, TN, <sup>4<\/sup>University of Pennsylvania, Philadelphia, PA, <sup>5<\/sup>University of Utah, Salt Lake City, UT, <sup>6<\/sup>Georges-Pompidou European Hospital, Paris, France, <sup>7<\/sup>University of Michigan, Ann Arbor, MI, <sup>8<\/sup>University of Pittsburgh, Pittsburgh, PA, <sup>9<\/sup>Aarhus University Hospital, Aarhus, Denmark, <sup>10<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>11<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"4b9381b9-0e53-44ed-8062-ae7d5572d507","ControlNumber":"10327","DisclosureBlock":"<b>&nbsp;R. Srinivasan, <\/b> <br><b>Peloton\/Merck<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Nikang Therapeutics<\/b> Grant\/Contract. <br><b>O. Iliopoulos, <\/b> <br><b>Merck<\/b> Other, Advisory Role.<br><b>K. E. Beckermann, <\/b> None.&nbsp;<br><b>V. Narayan, <\/b> <br><b>Regeneron<\/b> Other, Advisory Board. <br><b>Eisai<\/b> Other, Advisory Board. <br><b>Exelixis<\/b> Other, Advisory Board. <br><b>Janssen<\/b> Other, Advisory Board. <br><b>Sanofi<\/b> Other, Advisory Board. <br><b>Merck<\/b> Other, Research Grant. <br><b>Janssen<\/b> Other, Research Grant. <br><b>Pfizer<\/b> Other, Research Grant. <br><b>Regeneron<\/b> Other, Research Grant. <br><b>Bristol Myers Squibb<\/b> Other, Research Grant. <br><b>B. L. Maughan, <\/b> <br><b>Abbvie<\/b> Other, Paid Consultant\/Advisor. <br><b>Pfizer<\/b> Paid Consultant\/Advisor. <br><b>AVEO oncology<\/b> Other, Paid Consultant\/Advisor. <br><b>Janssen<\/b> Other, Paid Consultant\/Advisor. <br><b>Astellas<\/b> Other, Paid Consultant\/Advisor. <br><b>Bristol-Myers Squibb<\/b> Other, Paid Consultant\/Advisor. <br><b>Clovis<\/b> Other, Paid Consultant\/Advisor. <br><b>Tempus<\/b> Other, Paid Consultant\/Advisor. <br><b>Merck<\/b> Other, Paid Consultant\/Advisor. <br><b>Exelixis<\/b> Other, Paid Consultant\/Advisor. <br><b>Bayer Oncology<\/b> Other, Paid Consultant\/Advisor. <br><b>Lilly<\/b> Other, Paid Consultant\/Advisor. <br><b>Sanofi<\/b> Other, Paid Consultant\/Advisor. <br><b>Telix<\/b> Other, Paid Consultant\/Advisor. <br><b>Peloton Therapeutics<\/b> Other, Paid Consultant\/Advisor. <br><b>Huntsman Cancer Institute<\/b> Other, Huntsman Cancer Institute has received research funding from Exelixis (Inst), Bavarian-Nordic (Inst), Clovis (Inst), Genentech (Inst) and Bristol-Myers Squibb (Inst) on behalf of Dr. Linehan Marston.<br><b>S. Oudard, <\/b> None.&nbsp;<br><b>T. Else, <\/b> <br><b>Corcept<\/b> Other, Funding. <br><b>Merck<\/b> Other, Advisory Role. <br><b>Lantheus<\/b> Other, Advisory Role. <br><b>HRA<\/b> Other, Advisory Role. <br><b>J. K. Maranchie, <\/b> <br><b>Elsevier<\/b> Other, Editorial. <br><b>LUGPA<\/b> Other, Invited Speaker. <br><b>Merck<\/b> Other, Sponsor\/Funding. <br><b>Janssen<\/b> Other, Sponsor\/Funding. <br><b>Exelixis<\/b> Other, Provision of drug for study.<br><b>A. B. Iversen, <\/b> None.&nbsp;<br><b>J. Cornell, <\/b> <br><b>Merck & Co, Inc.<\/b> Employment, Stock. <br><b>R. F. Perini, <\/b> <br><b>Merck & Co, Inc.<\/b> Employment, Stock. <br><b>Y. Liu, <\/b> <br><b>Merck & Co, Inc.<\/b> Employment, Stock.<br><b>W. M. Linehan, <\/b> None.&nbsp;<br><b>E. Jonasch, <\/b> <br><b>Aveo<\/b> Other, Advisory Board. <br><b>Eisai<\/b> Other, Advisory Board. <br><b>Exelixis<\/b> Other, Advisory Board. <br><b>Ipsen<\/b> Other, Advisory Board. <br><b>Merck<\/b> Other, Advisory Board. <br><b>NiKang<\/b> Other, Advisory Board. <br><b>Novartis<\/b> Other, Advisory Board. <br><b>Telix<\/b> Other, Advisory Board. <br><b>Aveo<\/b> funding, principal investigator. <br><b>Arrowhead<\/b> Other, funding, principal investigator. <br><b>Corvus<\/b> Other, funding, principal investigator. <br><b>Merck<\/b> Other, funding, principal investigator. <br><b>NiKang<\/b> Other, funding, principal investigator. <br><b>Telix<\/b> Other, funding, principal investigator.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11556","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT221","PresenterBiography":null,"PresenterDisplayName":"Ramaprasad Srinivasan, MD;PhD","PresenterKey":"21dd274e-6049-4b9c-b782-1bc3a130ad30","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT221. Belzutifan, a hypoxia-inducible factor-2&#945; (HIF-2&#945;) inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: Long-term results of the phase 2 LITESPARK-004 study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Belzutifan, a hypoxia-inducible factor-2&#945; (HIF-2&#945;) inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: Long-term results of the phase 2 LITESPARK-004 study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Solid tumors,Genitourinary cancers: prostate,DNA damage response,Synthetic lethality,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. Aggarwal<\/b><sup>1<\/sup>, A. Italiano<sup>2<\/sup>, S. Domchek<sup>3<\/sup>, O. Goodman<sup>4<\/sup>, S. Postel-Vinay<sup>5<\/sup>, J. Garcia-Donas<sup>6<\/sup>, T. Dorff<sup>7<\/sup>, Z. Reichert<sup>8<\/sup>, P. Cassier<sup>9<\/sup>, N. Shore<sup>10<\/sup>, C. Marshall<sup>11<\/sup>, G. Parr<sup>12<\/sup>, I. Irurzun-Arana<sup>12<\/sup>, N. Shah<sup>13<\/sup>, N. Lukashchuk<sup>12<\/sup>, O. Murina<sup>12<\/sup>, D. Slade<sup>12<\/sup>, B. Loembé<sup>12<\/sup>, E. Dean<sup>12<\/sup>, E. Sanai<sup>12<\/sup>, W. Abida<sup>14<\/sup>; <br\/><sup>1<\/sup>University of California San Francisco, San Francisco, CA, <sup>2<\/sup>Institut Bergonié, Bordeaux, France, <sup>3<\/sup>Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA, <sup>4<\/sup>Comprehensive Cancer Centers of Nevada, Las Vegas, NV, <sup>5<\/sup>Institut Gustave Roussy, Villejuif, France, <sup>6<\/sup>HM Hospitales – Centro Integral Oncológico HM Clara Campal, Madrid, Spain, <sup>7<\/sup>City of Hope Comprehensive Cancer Center, Duarte, CA, <sup>8<\/sup>University of Michigan, Rogel Comprehensive Cancer Center, Ann Arbor, MI, <sup>9<\/sup>Department of Medical Oncology, Centre Léon Bérard, Lyon, France, <sup>10<\/sup>Carolina Urologic Research Center, Myrtle Beach, SC, <sup>11<\/sup>Johns Hopkins University, Baltimore, MD, <sup>12<\/sup>AstraZeneca, Cambridge, United Kingdom, <sup>13<\/sup>AstraZeneca, Waltham, MA, <sup>14<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY","CSlideId":"","ControlKey":"f7c003c9-5708-45ca-ac3a-0ff63a6411db","ControlNumber":"9881","DisclosureBlock":"<b>&nbsp;R. Aggarwal, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract.<br><b>A. Italiano, <\/b> None.&nbsp;<br><b>S. Domchek, <\/b> <br><b>GSK<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Independent Contractor. <br><b>O. Goodman, <\/b> <br><b>Janssen<\/b> Other, Speaker's bureau; Consultant. <br><b>AstraZeneca<\/b> Other, Speaker's bureau; Consultant. <br><b>S. Postel-Vinay, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>AMGEN<\/b> Grant\/Contract, Other, Advisory board. <br><b>imCORE<\/b> Grant\/Contract. <br><b>Hoffman-La Roche<\/b> Grant\/Contract. <br><b>Daiichi Sankyo<\/b> Other, Advisory board. <br><b>J. Garcia-Donas, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>MSD<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract. <br><b>Ipsen<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Janssen<\/b> Grant\/Contract. <br><b>Astellas<\/b> Grant\/Contract. <br><b>T. Dorff, <\/b> <br><b>Bayer<\/b> Other, Advisory board. <br><b>Janssen<\/b> Other, Advisory board. <br><b>AstraZeneca<\/b> Other, Advisory board. <br><b>Z. Reichert, <\/b> <br><b>AstraZeneca<\/b> Other, Consulting. <br><b>Janssen<\/b> Other, Consulting. <br><b>P. Cassier, <\/b> <br><b>OSE Immunotherapies<\/b> Independent Contractor. <br><b>Boehringer Ingelheim<\/b> Independent Contractor. <br><b>Bristol Myers Squibb<\/b> Independent Contractor. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Toray Industries<\/b> Travel. <br><b>N. Shore, <\/b> <br><b>Photocure<\/b> Fiduciary Officer, Independent Contractor. <br><b>Abbvie;Accord;Alessa Therapeutics;Amgen;Antev;Arquer;Asieris;Astellas;Astra Zeneca;Aura Biosciences;Bayer;Bioprotect;Bristol Myers Squibb;Boston Scientific;Cgoncology;Clarity;Cold Genesys;Dendreon;<\/b> Independent Contractor. <br><b>Exact Imaging;Genetech\/Roche;Ferring;Fize Medical;Foundation Medicine;Genesis Care;Immunity Bio;Incyte;Invitae;Janssen;Lantheus;Lilly;Mdxhealth;Merck;Minomic;Myovant;Myriad;Nonagen;Novartis;Nymox<\/b> Independent Contractor. <br><b>Palette Life;Platformq;Pacific Edge;Pfizer;Preview;Profound Medical;Promaxo;Protara;Photocure;Propella;Sanofi Genzyme;Speciality Networks;Telix;Tolmar;Urogen<\/b> Independent Contractor. <br><b>C. Marshall, <\/b> <br><b>Tempus<\/b> Independent Contractor. <br><b>Bayer<\/b> Independent Contractor. <br><b>ObsEva<\/b> Independent Contractor. <br><b>Astellas<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>G. Parr, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock Option. <br><b>I. Irurzun-Arana, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>N. Shah, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>N. Lukashchuk, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>O. Murina, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>D. Slade, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>B. Loembé, <\/b> <br><b>AstraZeneca<\/b> Stock, Other, Former employment. <br><b>E. Dean, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock, Stock Option, Patent. <br><b>E. Sanai, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>W. Abida, <\/b> <br><b>Roche<\/b> Other, Honoraria. <br><b>Medscape<\/b> Other, Honoraria. <br><b>Aptitude Health<\/b> Other, Honoraria. <br><b>Clinical Education Alliance<\/b> Other, Honoraria. <br><b>OncLive\/MJH Life Sciences<\/b> Other, Honoraria. <br><b>touchIME<\/b> Other, Honoraria. <br><b>Pfizer<\/b> Other, Honoraria; Consulting\/Advisory. <br><b>theMedNet<\/b> Other, Honoraria. <br><b>Clovis Oncology<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Janssen<\/b> Other, Consulting\/Advisory. <br><b>ORIC Pharmaceutical<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Daiichi Sankyo<\/b> Other, Consulting\/Advisory. <br><b>AstraZeneca\/MedImmune<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Zenith Epigenetics<\/b> Grant\/Contract. <br><b>Epizyme<\/b> Grant\/Contract. <br><b>Nuvation Bio<\/b> Grant\/Contract.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11557","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT222","PresenterBiography":null,"PresenterDisplayName":"Jordan Best","PresenterKey":"09caff0e-0e82-4e63-92a0-4dbc38fa90bc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT222. Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC)<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC)<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Dormancy,Prostate cancer,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>V. G. Patel<\/b><sup>1<\/sup>, D. Singh<sup>2<\/sup>, H. Joshi<sup>1<\/sup>, B. Liaw<sup>1<\/sup>, C.-K. Tsao<sup>1<\/sup>, M. Galsky<sup>1<\/sup>, L. Diamond<sup>1<\/sup>, J. Agguire-Ghiso<sup>2<\/sup>, W. Oh<sup>1<\/sup>; <br\/><sup>1<\/sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2<\/sup>Department of Cell Biology, Cancer Dormancy and Tumor Microenvironment Institute, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY","CSlideId":"","ControlKey":"d6b1bb45-b6f7-48ba-a639-f0016883dd24","ControlNumber":"10310","DisclosureBlock":"<b>&nbsp;V. G. Patel, <\/b> <br><b>Arvinas<\/b> Employment, Stock, Stock Option. <br><b>Seagen<\/b> Consulting. <br><b>Sanofi<\/b> Other, Consulting. <br><b>Crispr therapeutics<\/b> Stock. <br><b>Iovance Therapeutics<\/b> Stock. <br><b>Syndax Pharmaceuticals<\/b> Stock. <br><b>Exact Biosciences<\/b> Stock. <br><b>Bellicum Pharmaceuticals<\/b> Stock. <br><b>Finch Therapeutics<\/b> Stock.<br><b>D. Singh, <\/b> None..<br><b>H. Joshi, <\/b> None.&nbsp;<br><b>B. Liaw, <\/b> <br><b>Daiichi Sankyo<\/b> Other, Consulting. <br><b>Eisai<\/b> Other, Consulting. <br><b>Exelixis<\/b> Other, Consulting. <br><b>Myovant Biosciences<\/b> Other, Consulting. <br><b>EMD Serono<\/b> Other, Consulting. <br><b>Epizyme<\/b> Other, Consulting. <br><b>Janssen Biotech<\/b> Other, Consulting. <br><b>Bristol Myers Squibb<\/b> Other, Consulting. <br><b>Bayer<\/b> Grant\/Contract. <br><b>Sanofi<\/b> Grant\/Contract. <br><b>C. Tsao, <\/b> <br><b>Exelixis<\/b> Grant\/Contract, Other, Consulting. <br><b>Eisai<\/b> Other, Consulting. <br><b>Sanofi<\/b> Other, Consulting. <br><b>Bristol Myers Squibb<\/b> Other, Consulting. <br><b>M. Galsky, <\/b> <br><b>Bristol Myers Squibb<\/b> Other, Consulting. <br><b>Novartis<\/b> Other, Consulting. <br><b>Dendreon<\/b> Other, Consulting. <br><b>AstraZaneca<\/b> Other, Consulting. <br><b>Merck<\/b> Other, Consulting. <br><b>Genentech<\/b> Grant\/Contract. <br><b>EMD Serono<\/b> Other, Consulting. <br><b>Seagen<\/b> Other, Consulting. <br><b>Janssen<\/b> Other, Consulting. <br><b>Numab<\/b> Other, Consulting. <br><b>Dragonfly<\/b> Other, Consulting. <br><b>GlaxoSmithKline<\/b> Other, Consulting. <br><b>Basilea<\/b> Other, Consulting. <br><b>UroGen<\/b> Other, Consulting. <br><b>Alligator Biosciences<\/b> Other, Consulting. <br><b>Curis<\/b> Other, Consulting. <br><b>Rappta Therapeutics<\/b> Other Business Ownership, Other, Consulting.<br><b>L. Diamond, <\/b> None.&nbsp;<br><b>J. Agguire-Ghiso, <\/b> <br><b>HiberCell<\/b> Other Business Ownership, Other, Scientific Advisory Board, Consulting. <br><b>W. Oh, <\/b> <br><b>Sanofi<\/b> Other, Consulting. <br><b>Janssen<\/b> Other, Consulting. <br><b>AstraZaneca<\/b> Other, Consulting. <br><b>Bayer<\/b> Other, Consulting. <br><b>Huya Bioscience<\/b> Other, Consulting. <br><b>TeneBio<\/b> Other, Consulting. <br><b>Advanced Accelerator Applications<\/b> Other, Consulting. <br><b>Foundry<\/b> Other, Consulting. <br><b>GlaxoSmithKline<\/b> Other, Consulting. <br><b>Merck<\/b> Other, Consulting. <br><b>Pfizer<\/b> Other, Consulting.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11558","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"22","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT223","PresenterBiography":null,"PresenterDisplayName":"Vaibhav Patel, MD","PresenterKey":"06aa7db4-ad6b-45ae-adc8-96c311cb4950","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT223. Dormancy reprograming therapy of 5-azacitidine (AZA) and all-trans retinoic acid (ATRA) in biochemically recurrent prostate cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Dormancy reprograming therapy of 5-azacitidine (AZA) and all-trans retinoic acid (ATRA) in biochemically recurrent prostate cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Targeted alpha therapy,Prostate cancer,Prostate-specific membrane antigen (PSMA),Prostate-specific antigen (PSA),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"E. S. Delpassand<sup>1<\/sup>, M. J. Hashmi<sup>1<\/sup>, J. Kazakin<sup>2<\/sup>, O. Nawaz<sup>2<\/sup>, G. Garufi<sup>2<\/sup>, J. Schindler<sup>2<\/sup>, <b>L. Nordquist<\/b><sup>3<\/sup>; <br\/><sup>1<\/sup>Excel Diagnostics and Nuclear Oncology Center, Houston, TX, <sup>2<\/sup>Fusion Pharmaceuticals Inc., Boston, MA, <sup>3<\/sup>XCancer Omaha, Omaha, NE","CSlideId":"","ControlKey":"04bc85ac-c142-409f-9e6c-53f270456819","ControlNumber":"10801","DisclosureBlock":"&nbsp;<b>E. S. Delpassand, <\/b> None..<br><b>M. J. Hashmi, <\/b> None.&nbsp;<br><b>J. Kazakin, <\/b> <br><b>Fusion Pharmaceuticals Inc<\/b> Employment, Stock, Stock Option. <br><b>O. Nawaz, <\/b> <br><b>Fusion Pharmaceuticals Inc<\/b> Employment, Stock, Stock Option. <br><b>G. Garufi, <\/b> <br><b>Fusion Pharmaceuticals Inc<\/b> Employment, Stock, Stock Option. <br><b>J. Schindler, <\/b> <br><b>Fusion Pharmaceuticals Inc<\/b> Employment, Stock, Stock Option.<br><b>L. Nordquist, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11559","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"23","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT224","PresenterBiography":null,"PresenterDisplayName":"Brigitte Theriault, PhD","PresenterKey":"aa9a6802-18c4-474b-9304-b2decbfd434f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT224. Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (<sup>225<\/sup>Ac-PSMA-I&#38;T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (<sup>225<\/sup>Ac-PSMA-I&#38;T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Prostate-specific membrane antigen (PSMA),Prostate cancer,Radiopharmaceuticals,Quantitative imaging,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. T. Nauseef<sup>1<\/sup>, C. Thomas<sup>1<\/sup>, M. Sun<sup>1<\/sup>, N. Jacobs<sup>1<\/sup>, <b>A. Ricaurte Fajardo<\/b><sup>1<\/sup>, S. Ruder<sup>1<\/sup>, E. Fernandez<sup>1<\/sup>, Z. Davidson<sup>1<\/sup>, A. Patel<sup>1<\/sup>, A. Sartor<sup>2<\/sup>, S. Vallabhajosula<sup>1<\/sup>, A. Molina<sup>1<\/sup>, C. N. Sternberg<sup>1<\/sup>, D. M. Nanus<sup>1<\/sup>, S. Huicochea Castellanos<sup>1<\/sup>, J. Osborne<sup>1<\/sup>, N. H. Bander<sup>1<\/sup>, T. Perk<sup>3<\/sup>, S. Tagawa<sup>1<\/sup>; <br\/><sup>1<\/sup>Weill Cornell Medicine\/Sandra and Edward Meyer Cancer Center, New York, NY, <sup>2<\/sup>Mayo Clinic, Rochester, MN, <sup>3<\/sup>AIQ Solutions, Inc, Madison, WI","CSlideId":"","ControlKey":"bcaf2bc8-9063-4434-837f-cb1657d9803a","ControlNumber":"10557","DisclosureBlock":"<b>&nbsp;J. T. Nauseef, <\/b> <br><b>Pfizer<\/b> Independent Contractor, Travel. <br><b>Bayer<\/b> Independent Contractor. <br><b>AIQ<\/b> Independent Contractor.<br><b>C. Thomas, <\/b> None..<br><b>M. Sun, <\/b> None..<br><b>N. Jacobs, <\/b> None..<br><b>A. Ricaurte Fajardo, <\/b> None..<br><b>S. Ruder, <\/b> None..<br><b>E. Fernandez, <\/b> None..<br><b>Z. Davidson, <\/b> None..<br><b>A. Patel, <\/b> None..<br><b>A. Sartor, <\/b> None.&nbsp;<br><b>S. Vallabhajosula, <\/b> <br><b>Convergent Therapeutics<\/b> Employment.<br><b>A. Molina, <\/b> None..<br><b>C. N. Sternberg, <\/b> None..<br><b>D. M. Nanus, <\/b> None..<br><b>S. Huicochea Castellanos, <\/b> None..<br><b>J. Osborne, <\/b> None.&nbsp;<br><b>N. H. Bander, <\/b> <br><b>Convergent Therapeutics<\/b> Stock Option, Other Business Ownership, Other Intellectual Property. <br><b>T. Perk, <\/b> <br><b>AIQ Solutions, Inc.<\/b> Employment.<br><b>S. Tagawa, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11560","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"24","PosterboardNumber":"25","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT225","PresenterBiography":null,"PresenterDisplayName":"Andres Ricaurte Fajardo, MD","PresenterKey":"bb57d0bc-3163-494e-bf64-fc2906dc27f0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT225. Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I\/II trial","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I\/II trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Head and neck squamous cell carcinoma,CCR4,Regulatory T cells,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Muzaffar<\/b><sup>1<\/sup>, K. Kirtane<sup>2<\/sup>, R. Redman<sup>3<\/sup>, M.-H. Yang<sup>4<\/sup>, T. Kim<sup>5<\/sup>, S. Liu<sup>6<\/sup>, R. Lynch<sup>7<\/sup>, J. Brahmer<sup>8<\/sup>, P. LoRusso<sup>9<\/sup>, B. Henick<sup>10<\/sup>, S.-b. Kim<sup>11<\/sup>, Y.-H. Feng<sup>12<\/sup>, M. Chisamore<sup>13<\/sup>, P. Kassner<sup>14<\/sup>, D. Brockstedt<sup>14<\/sup>, N. Nasrah<sup>14<\/sup>, R. Goyal<sup>14<\/sup>, W. Y. Ho<sup>14<\/sup>, V. Villaflor<sup>15<\/sup>; <br\/><sup>1<\/sup>Duke University School of Medicine, Durham, NC, <sup>2<\/sup>Moffitt Cancer Center, Tampa, FL, <sup>3<\/sup>University of Louisville Brown Cancer Center, Louisville, KY, <sup>4<\/sup>Taipei Veterans General Hospital, Taipei City, Taiwan, <sup>5<\/sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>6<\/sup>Georgetown University, Washington, DC, <sup>7<\/sup>University of Washington, Seattle, WA, <sup>8<\/sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>9<\/sup>Yale School of Medicine, New Haven, CT, <sup>10<\/sup>Columbia University, New York, NY, <sup>11<\/sup>Asan Medical Center, Seoul, Korea, Republic of, <sup>12<\/sup>Chi Mei Medical Center, Tainan, Taiwan, <sup>13<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>14<\/sup>RAPT Therapeutics, Inc., South San Francisco, CA, <sup>15<\/sup>City of Hope, Duarte, CA","CSlideId":"","ControlKey":"8f72a4f6-c1ac-4ac9-a33d-e137ca773d8c","ControlNumber":"10332","DisclosureBlock":"<b>&nbsp;J. Muzaffar, <\/b> <br><b>Exelixis<\/b> Other, Advisory board. <br><b>Oncominds<\/b> Other, Meeting panelist. <br><b>K. Kirtane, <\/b> <br><b>SeaGen<\/b> Stock. <br><b>Oncternal Therapeutics<\/b> Stock. <br><b>Veru<\/b> Stock. <br><b>A2Biotherapeutics<\/b> Other, Advisory board. <br><b>MyCareGorithm, LLC.<\/b> Other, Advisory board. <br><b>R. Redman, <\/b> <br><b>ALX Oncology<\/b> Other, Research funding. <br><b>Daiichi Sankyo<\/b> Other, Research funding. <br><b>Inspirna<\/b> Other, Research funding. <br><b>Iovance<\/b> Other, Research funding. <br><b>Merck<\/b> Other, Research funding. <br><b>Molecular Templates<\/b> Other, Research funding. <br><b>Pfizer<\/b> Other, Research funding. <br><b>RAPT Therapeutics<\/b> Other, Research funding.<br><b>M. Yang, <\/b> None.&nbsp;<br><b>T. Kim, <\/b> <br><b>Amgen<\/b> Other, Consultancy and research funding. <br><b>AstraZeneca<\/b> Other, Consultancy and research funding. <br><b>Bayer<\/b> Other, Research funding. <br><b>BMS<\/b> Other, Research funding. <br><b>Boehringer Ingelheim<\/b> Other, Research funding. <br><b>Boryung<\/b> Other, Research funding. <br><b>Celgene<\/b> Other, Research funding. <br><b>Genmab<\/b> Other, Research funding. <br><b>Hanmi<\/b> Other, Research funding. <br><b>Janssen<\/b> Other, Consultancy and research funding. <br><b>Merck Sharp & Dohme<\/b> Other, Consultancy and research funding. <br><b>Novartis<\/b> Other, Consultancy and research funding. <br><b>RAPT Therapeutics<\/b> Other, Research funding. <br><b>Regeneron<\/b> Other, Consultancy and research funding. <br><b>Roche\/Genentech<\/b> Other, Research funding. <br><b>Sanofi<\/b> Other, Research funding. <br><b>Takeda<\/b> Other, Consultancy and research funding. <br><b>Daiichi Sankyo<\/b> Other, Consultancy. <br><b>Samsung Bioepis<\/b> Other, Consultancy. <br><b>Yuhan<\/b> Other, Consultancy.<br><b>S. Liu, <\/b> None.&nbsp;<br><b>R. Lynch, <\/b> <br><b>TG Therapeutics<\/b> Other, Research funding. <br><b>Incyte<\/b> Other, Research funding. <br><b>Bayer<\/b> Other, Research funding. <br><b>Cyteir<\/b> Other, Research funding. <br><b>Genentech<\/b> Other, Research funding. <br><b>SeaGen<\/b> Other, Research funding, consultancy\/honoraria. <br><b>RAPT Therapeutics<\/b> Other, Research funding. <br><b>Merck<\/b> Other, Research funding, consultancy\/honoraria. <br><b>Foresight Diagnostics<\/b> Other, Consultancy\/honoraria. <br><b>AbbVie<\/b> Other, Consultancy\/honoraria. <br><b>Janssen<\/b> Other, Consultancy\/honoraria.<br><b>J. Brahmer, <\/b> None..<br><b>P. LoRusso, <\/b> None..<br><b>B. Henick, <\/b> None.&nbsp;<br><b>S. Kim, <\/b> <br><b>Novartis<\/b> Other, Research finding, consultancy. <br><b>Sanofi-Aventis<\/b> Other, Research funding. <br><b>DongKook Pharm Co.<\/b> Other, Research funding. <br><b>AstraZeneca<\/b> Other, Consultancy. <br><b>Lilly<\/b> Other, Consultancy. <br><b>Dae Hwa Pharmaceutical Co. Ltd.<\/b> Other, Consultancy. <br><b>ISU Abxis<\/b> Other, Consultancy. <br><b>OBI Pharma<\/b> Other, Consultancy. <br><b>Beigene<\/b> Other, Consultancy. <br><b>Genopeaks<\/b> Stock. <br><b>Neogene TC<\/b> Stock.<br><b>Y. Feng, <\/b> None.&nbsp;<br><b>M. Chisamore, <\/b> <br><b>Merck<\/b> Employment. <br><b>P. Kassner, <\/b> <br><b>RAPT Therapeutics, Inc.<\/b> Employment. <br><b>D. Brockstedt, <\/b> <br><b>RAPT Therapeutics, Inc.<\/b> Employment. <br><b>N. Nasrah, <\/b> <br><b>RAPT Therapeutics, Inc.<\/b> Employment. <br><b>R. Goyal, <\/b> <br><b>RAPT Therapeutics, Inc.<\/b> Employment. <br><b>W. Y. Ho, <\/b> <br><b>RAPT Therapeutics, Inc.<\/b> Employment, Stock, Stock Option. <br><b>V. Villaflor, <\/b> <br><b>Johnson & Johnson<\/b> Stock. <br><b>Takeda Science Foundation<\/b> Other, Research funding. <br><b>ARIAD\/Takeda<\/b> Travel, Other, Consultancy. <br><b>AstraZeneca<\/b> Travel, Other, Consultancy. <br><b>BMS<\/b> Travel, Other, Consultancy. <br><b>Novacure<\/b> Travel, Other, Consultancy. <br><b>Regeneron<\/b> Travel, Other, Consultancy. <br><b>Gilead<\/b> Travel, Other, Consultancy. <br><b>Genentech\/Roche<\/b> Other, Consultancy.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11561","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"25","PosterboardNumber":"26","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT226","PresenterBiography":null,"PresenterDisplayName":"Jameel Muzaffar, MD","PresenterKey":"c82274be-3fbc-4cb9-8aed-8d6fa2030121","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT226. Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Nasopharyngeal carcinoma,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Yunpeng Yang<sup>1<\/sup>, Yuanyuan Zhao<sup>1<\/sup>, Wenfeng Fang<sup>1<\/sup>, Yan Huang<sup>1<\/sup>, Yaxiong Zhang<sup>1<\/sup>, Yi Ba<sup>2<\/sup>, Zhen Wang<sup>3<\/sup>, Chao Deng<sup>4<\/sup>, Desheng Hu<sup>5<\/sup>, Wei Wang<sup>6<\/sup>, Guiling Li<sup>7<\/sup>, Suxia Luo<sup>8<\/sup>, Zhichao Fu<sup>9<\/sup>, Haisheng Zhu<sup>10<\/sup>, Huili Wang<sup>11<\/sup>, Shiwei Zhao<sup>12<\/sup>, Tao Li<sup>12<\/sup>, Charles Cai<sup>12<\/sup>, <b>Li Zhang<\/b><sup>1<\/sup><br><br\/><sup>1<\/sup>Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China,<sup>2<\/sup>Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China,<sup>3<\/sup>Department of Oncology, Linyi Cancer Hospital, Linyi, China,<sup>4<\/sup>Cancer Center, Chong Qing University Three Gorges Hospital, Chongqing, China,<sup>5<\/sup>Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, China,<sup>6<\/sup>Gastroenterology and Urology Department &#8545;, Hunan Cancer Hospital, Changsha, China,<sup>7<\/sup>Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,<sup>8<\/sup>Department of Oncology, Henan Cancer Hospital, Zhengzhou, China,<sup>9<\/sup>Department of radiotherapy, No. 900 Hospital of the PLA Joint Logistics Support Force, Fuzhou, China,<sup>10<\/sup>Department of Oncology, The First People's Hospital of Yulin, Yulin, China,<sup>11<\/sup>Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, China,<sup>12<\/sup>Leads Biolabs, Nanjing, China","CSlideId":"","ControlKey":"78b2c655-094c-44e4-86c0-51b8ad215486","ControlNumber":"10345","DisclosureBlock":"&nbsp;<b>Y. Yang, <\/b> None..<br><b>Y. Zhao, <\/b> None..<br><b>W. Fang, <\/b> None..<br><b>Y. Huang, <\/b> None..<br><b>Y. Zhang, <\/b> None..<br><b>Y. Ba, <\/b> None..<br><b>Z. Wang, <\/b> None..<br><b>C. Deng, <\/b> None..<br><b>D. Hu, <\/b> None..<br><b>W. Wang, <\/b> None..<br><b>G. Li, <\/b> None..<br><b>S. Luo, <\/b> None..<br><b>Z. Fu, <\/b> None..<br><b>H. Zhu, <\/b> None..<br><b>H. Wang, <\/b> None.&nbsp;<br><b>S. Zhao, <\/b> <br><b>Leads Biolabs<\/b> Employment. <br><b>T. Li, <\/b> <br><b>Leads Biolabs<\/b> Employment. <br><b>C. Cai, <\/b> <br><b>Leads Biolabs<\/b> Employment.<br><b>L. Zhang, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11562","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"26","PosterboardNumber":"27","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT227","PresenterBiography":null,"PresenterDisplayName":"Li Zhang, MD","PresenterKey":"9e60605b-8a20-4d76-85f0-0e979171b94a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT227. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib\/II, open-label, multicenter, dose escalation\/expansion study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"615","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 1","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib\/II, open-label, multicenter, dose escalation\/expansion study","Topics":null,"cSlideId":""}]